

1 Novel risk loci for COVID-19 hospitalization among 2 admixed American populations

3 Silvia Diz-de Almeida,^{1,2,135} Raquel Cruz,^{1,2,135} Andre D. Luchessi,³ José M. Lorenzo-Salazar,⁴
4 Miguel López de Heredia,² Inés Quintela,⁵ Rafaela González-Montelongo,⁴ Vivian N. Silbiger,³
5 Marta Sevilla Porras,^{2,6} Jair Antonio Tenorio Castaño,^{2,6,7} Julian Nevado,^{2,6,7} Jose María
6 Aguado,^{8,9,10,11} Carlos Aguilar,¹² Sergio Aguilera-Albesa,^{13,14} Virginia Almadana,¹⁵ Berta
7 Almoguera,^{16,2} Nuria Alvarez,¹⁷ Álvaro Andreu-Bernabeu,^{18,10} Eunáte Arana-Arri,^{19,20} Celso
8 Arango,^{18,21,10} María J. Arranz,²² Maria-Jesus Artiga,²³ Raúl C. Baptista-Rosas,^{24,25,26} María
9 Barreda- Sánchez,^{27,28} Moncef Belhassen-Garcia,^{29,30} Joao F. Bezerra,³¹ Marcos A.C. Bezerra,³²
10 Lucía Boix-Palop,³³ María Brion,^{34,35} Ramón Brugada,^{36,37,35,38} Matilde Bustos,³⁹ Enrique J.
11 Calderón,^{39,40,41} Cristina Carbonell,^{42,30} Luis Castano,^{19,43,2,44,45} Jose E. Castelao,⁴⁶ Rosa Conde-
12 Vicente,⁴⁷ M. Lourdes Cordero-Lorenzana,⁴⁸ Jose L. Cortes-Sanchez,^{49,50} Marta Corton,^{16,2} M.
13 Teresa Darnaude,⁵¹ Alba De Martino-Rodríguez,^{52,53} Victor del Campo-Pérez,⁵⁴ Aranzazu Diaz
14 de Bustamante,⁵¹ Elena Domínguez-Garrido,⁵⁵ Rocío Eirós,⁵⁶ María Carmen Fariñas,^{57,58,59}
15 María J. Fernandez-Nestosa,⁶⁰ Uxía Fernández-Robelo,⁶¹ Amanda Fernández-Rodríguez,^{62,11}
16 Tania Fernández-Villa,^{63,41} Manuela Gago-Domínguez,^{5,64} Belén Gil-Fournier,⁶⁵ Javier Gómez-
17 Arrue,^{52,53} Beatriz González Álvarez,^{52,53} Fernan Gonzalez Bernaldo de Quirós,⁶⁶ Anna
18 González-Neira,¹⁷ Javier González-Peñas,^{18,10,21} Juan F. Gutiérrez-Bautista,⁶⁷ María José
19 Herrero,^{68,69} Antonio Herrero-Gonzalez,⁷⁰ María A. Jimenez-Sousa,^{62,11} María Claudia Lattig,^{71,72}
20 Anabel Liger Borja,⁷³ Rosario Lopez-Rodriguez,^{16,2,74} Esther Mancebo,^{75,76} Caridad Martín-
21 López,⁷³ Vicente Martín,⁶³ Oscar Martínez-Nieto,^{77,72} Iciar Martínez-Lopez,^{78,79} Michel F.
22 Martínez-Resendez,⁴⁹ Ángel Martínez-Perez,⁸⁰ Juliana F. Mazzeu,^{81,82,83} Eleuterio Merayo
23 Macías,⁸⁴ Pablo Minguez,^{16,2} Victor Moreno Cuerda,^{85,86} Silviene F. Oliveira,^{87,88,83,89} Eva
24 Ortega-Paino,²³ Mara Parellada,^{18,21,10} Estela Paz-Artal,^{75,76,90} Ney P.C. Santos,⁹¹ Patricia Pérez-
25 Matute,⁹² Patricia Perez,⁹³ M. Elena Pérez-Tomás,²⁷ Teresa Perucho,⁹⁴ Mel-lina Pinsach-
26 Abuin,^{36,35} Guillermo Pita,¹⁷ Ericka N. Pompa-Mera,^{95,96} Gloria L. Porras-Hurtado,⁹⁷ Aurora
27 Pujol,^{98,2,99} Soraya Ramiro León,⁶⁵ Salvador Resino,^{62,11} Marianne R. Fernandes,^{91,100} Emilio
28 Rodríguez-Ruiz,^{101,64} Fernando Rodriguez-Artalejo,^{102,103,41,104} José A. Rodriguez-Garcia,¹⁰⁵
29 Francisco Ruiz-Cabello,^{67,106,107} Javier Ruiz-Hornillos,^{108,109,110} Pablo Ryan,^{111,112,113,11} José
30 Manuel Soria,⁸⁰ Juan Carlos Souto,¹¹⁴ Eduardo Tamayo,^{115,116,11} Alvaro Tamayo-Velasco,¹¹⁷
31 Juan Carlos Taracido-Fernandez,⁷⁰ Alejandro Teper,¹¹⁸ Lilian Torres-Tobar,¹¹⁹ Miguel
32 Urioste,¹²⁰ Juan Valencia-Ramos,¹²¹ Zuleima Yáñez,¹²² Ruth Zarate,¹²³ Itziar de Rojas,^{124,125}
33 Agustín Ruiz,^{124,125} Pascual Sánchez,¹²⁶ Luis Miguel Real,¹²⁷ SCOURGE Cohort Group, Encarna
34 Guillen-Navarro,^{27,128,129,130} Carmen Ayuso,^{16,2} Esteban Parra,¹³¹ José A. Riancho,^{57,58,59,2}
35 Augusto Rojas-Martinez,¹³² Carlos Flores,^{4,133,134,136,*} Pablo Lapunzina,^{2,6,7,136} Ángel
36 Carracedo,^{1,2,5,64,136,**}

37 Affiliations

38 ¹, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS),
39 Universidade de Santiago de Compostela, Santiago de Compostela, Spain

40 ², CIBERER, ISCIII, Madrid, Spain

- 41 ³, Universidade Federal do Rio Grande do Norte, Departamento de Análises Clínicas e
42 Toxicológicas, Natal, Brazil
- 43 ⁴, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife,
44 Spain
- 45 ⁵, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
46 Santiago de Compostela, Spain
- 47 ⁶, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-
48 IDIPAZ, Madrid, Spain
- 49 ⁷, ERN-ITHACA-European Reference Network
- 50 ⁸, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
51 Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- 52 ⁹, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
53 Salud Carlos III, Madrid, Spain
- 54 ¹⁰, School of Medicine, Universidad Complutense, Madrid, Spain
- 55 ¹¹, CIBERINFEC, ISCIII, Madrid, Spain
- 56 ¹², Hospital General Santa Bárbara de Soria, Soria, Spain
- 57 ¹³, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
58 Pamplona, Spain
- 59 ¹⁴, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 60 ¹⁵, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 61 ¹⁶, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
62 Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 63 ¹⁷, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- 64 ¹⁸, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
65 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 66 ¹⁹, Biocruces Bizkai HRI, Bizkaia, Spain
- 67 ²⁰, Cruces University Hospital, Osakidetza, Bizkaia, Spain
- 68 ²¹, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
69 Carlos III, Madrid, Spain
- 70 ²², Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 71 ²³, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 72 ²⁴, Hospital General de Occidente, Zapopan Jalisco, Mexico
- 73 ²⁵, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá Jalisco, Mexico
- 74 ²⁶, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá
75 idisJalisco, Mexico

- 76 ²⁷, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- 77 ²⁸, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- 78 ²⁹, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
79 Enfermedades Infecciosas, Salamanca, Spain
- 80 ³⁰, Universidad de Salamanca, Salamanca, Spain
- 81 ³¹, Escola Técnica de Saúde, Laboratório de Vigilância Molecular Aplicada, Brazil
- 82 ³², Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 83 ³³, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- 84 ³⁴, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
85 Compostela, Spain
- 86 ³⁵, CIBERCV, ISCIII, Madrid, Spain
- 87 ³⁶, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
88 Spain
- 89 ³⁷, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 90 ³⁸, Hospital Josep Trueta, Cardiology Service, Girona, Spain
- 91 ³⁹, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
92 (CSIC)- University of Seville- Virgen del Rocío University Hospital, Seville, Spain
- 93 ⁴⁰, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
94 Seville, Spain
- 95 ⁴¹, CIBERESP, ISCIII, Madrid, Spain
- 96 ⁴², Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
97 Spain
- 98 ⁴³, Osakidetza, Cruces University Hospital, Bizkaia, Spain
- 99 ⁴⁴, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
100 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 101 ⁴⁵, University of Pais Vasco, UPV/EHU, Bizkaia, Spain
- 102 ⁴⁶, Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur, Xerencia de
103 Xestión Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 104 ⁴⁷, Hospital Universitario Río Hortega, Valladolid, Spain
- 105 ⁴⁸, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
106 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 107 ⁴⁹, Tecnológico de Monterrey, Monterrey, Mexico
- 108 ⁵⁰, Otto von Guericke University, Department of Microgravity and Translational Regenerative
109 Medicine, Magdeburg, Germany
- 110 ⁵¹, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain

- 111 ⁵², Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 112 ⁵³, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- 113 ⁵⁴, Preventive Medicine Department, Instituto de Investigación Sanitaria Galicia Sur, Xerencia
114 de Xestión Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 115 ⁵⁵, Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- 116 ⁵⁶, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 117 ⁵⁷, IDIVAL, Cantabria, Spain
- 118 ⁵⁸, Universidad de Cantabria, Cantabria, Spain
- 119 ⁵⁹, Hospital U M Valdecilla, Cantabria, Spain
- 120 ⁶⁰, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
- 121 ⁶¹, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
122 Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 123 ⁶², Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
124 de Salud Carlos III (ISCIII), Madrid, Spain
- 125 ⁶³, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) - Instituto de
126 Biomedicina (IBIOMED), Universidad de León, León, Spain
- 127 ⁶⁴, IDIS
- 128 ⁶⁵, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 129 ⁶⁶, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- 130 ⁶⁷, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
131 Granada, Spain
- 132 ⁶⁸, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 133 ⁶⁹, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 134 ⁷⁰, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
135 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 136 ⁷¹, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia
- 137 ⁷², SIGEN Alianza Universidad de los Andes - Fundación Santa Fe de Bogotá, Bogotá,
138 Colombia
- 139 ⁷³, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain
- 140 ⁷⁴, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización
141 Montepríncipe, 28660 Boadilla del Monte, España
- 142 ⁷⁵, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain
- 143 ⁷⁶, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
144 Immunology and Immunodeficiencies Group, Madrid, Spain

- 145 ⁷⁷, Fundación Santa Fe de Bogota, Departamento Patología y Laboratorios, Bogotá, Colombia
- 146 ⁷⁸, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- 147 ⁷⁹, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
148 Islas Baleares, Spain
- 149 ⁸⁰, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
150 Pau, IIB Sant Pau, Barcelona, Spain
- 151 ⁸¹, Universidade de Brasília, Faculdade de Medicina, Brazil
- 152 ⁸², Programa de Pós-Graduação em Ciências Médicas (UnB), Brazil
- 153 ⁸³, Programa de Pós-Graduação em Ciências da Saúde (UnB), Brazil
- 154 ⁸⁴, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 155 ⁸⁵, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain
- 156 ⁸⁶, Universidad Francisco de Vitoria, Madrid, Spain
- 157 ⁸⁷, Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
158 Brasília, Brazil
- 159 ⁸⁸, Programa de Pós-Graduação em Biologia Animal (UnB), Brazil
- 160 ⁸⁹, Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB), Brazil
- 161 ⁹⁰, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT,
162 Madrid, Spain
- 163 ⁹¹, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil
- 164 ⁹², Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
165 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 166 ⁹³, Inditex, A Coruña, Spain
- 167 ⁹⁴, GENYCA, Madrid, Spain
- 168 ⁹⁵, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
169 de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
- 170 ⁹⁶, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional La Raza. Hospital de
171 Infectología, Mexico City, Mexico
- 172 ⁹⁷, Clinica Comfamiliar Risaralda, Pereira, Colombia
- 173 ⁹⁸, Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
174 L'Hospitalet de Llobregat, Spain
- 175 ⁹⁹, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 176 ¹⁰⁰, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 177 ¹⁰¹, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
178 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain

179 ¹⁰², Department of Preventive Medicine and Public Health, School of Medicine, Universidad
180 Autónoma de Madrid, Madrid, Spain

181 ¹⁰³, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain

182 ¹⁰⁴, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain

183 ¹⁰⁵, Complejo Asistencial Universitario de León, León, Spain

184 ¹⁰⁶, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain

185 ¹⁰⁷, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
186 Granada, Spain

187 ¹⁰⁸, Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain

188 ¹⁰⁹, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
189 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain

190 ¹¹⁰, Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain

191 ¹¹¹, Hospital Universitario Infanta Leonor, Madrid, Spain

192 ¹¹², Complutense University of Madrid, Madrid, Spain

193 ¹¹³, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain

194 ¹¹⁴, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
195 Barcelona, Spain

196 ¹¹⁵, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiología y Reanimación,
197 Valladolid, Spain

198 ¹¹⁶, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain

199 ¹¹⁷, Hospital Clinico Universitario de Valladolid, Servicio de Hematología y Hemoterapia,
200 Valladolid, Spain

201 ¹¹⁸, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina

202 ¹¹⁹, Fundación Universitaria de Ciencias de la Salud

203 ¹²⁰, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain

204 ¹²¹, University Hospital of Burgos, Burgos, Spain

205 ¹²², Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia

206 ¹²³, Centro para el Desarrollo de la Investigación Científica, Paraguay

207 ¹²⁴ ¹⁸³, Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat
208 Internacional de Catalunya, Spain

209 ¹²⁵ ¹⁸⁴, Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),
210 Instituto de Salud Carlos III, Madrid, Spain

211 ¹²⁶ ¹⁸⁵, CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain

212 ¹²⁷ ¹⁸⁶, Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y
213 Microbiología, Sevilla, Spain

214 ¹²⁸ ¹²⁴, Sección Genética Médica - Servicio de Pediatría, Hospital Clínico Universitario Virgen
215 de la Arrixaca, Servicio Murciano de Salud, Murcia, Spain

216 ¹²⁹ ¹²⁵, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
217 Universidad de Murcia (UMU), Murcia, Spain

218 ¹³⁰ ¹²⁶, Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases
219 (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

220 ¹³¹ ¹²⁷ Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario,
221 Canada.

222 ¹³² ¹²⁸, Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey,
223 Mexico

224 ¹³³ ¹²⁹, Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de
225 Tenerife, Spain

226 ¹³⁴ ¹³⁰, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto
227 de Salud Carlos III, Madrid, Spain

228 ¹³⁵ ¹³¹, These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz

229 ¹³⁶ ¹³², These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo

230 *Correspondence: cflores@ull.edu.es

231 **Correspondence: angel.carracedo@usc.es

232

233 **Abstract**

234 The genetic basis of severe COVID-19 has been thoroughly studied and many genetic
235 risk factors shared between populations have been identified. However, reduced sample
236 sizes from non-European groups have limited the discovery of population-specific
237 common risk loci. In this second study nested in the SCOURGE consortium, we have
238 conducted the largest GWAS meta-analysis for COVID-19 hospitalization in admixed
239 Americans, comprising a total of 4,702 hospitalized cases recruited by SCOURGE and
240 other seven participating studies in the COVID-19 Host Genetic Initiative. We
241 identified four genome-wide significant associations, two of which constitute novel loci
242 and first discovered in Latin-American populations (*BAZ2B* and *DDIAS*). A trans-ethnic
243 meta-analysis revealed another novel cross-population risk locus in *CREBBP*. Finally,
244 we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE
245 admixed American cohort.

246 **Introduction**

247 To date, more than 50 loci associated to COVID-19 susceptibility, hospitalization, and
248 severity have been identified using genome-wide association studies (GWAS)^{1,2}. The
249 COVID-19 Host Genetics Initiative (HGI) has made significant efforts³ to augment the
250 power to identify disease loci by recruiting individuals from diverse populations and
251 conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and
252 a focus on cases of European ancestries still predominate in the studies^{4,5}. Besides,
253 while trans-ancestry meta-analyses are a powerful approach for discovering shared
254 genetic risk variants with similar effects across populations⁶, they may fail to identify
255 risk variants that have larger effects on particular underrepresented populations. Genetic
256 disease risk has been shaped by the particular evolutionary history of populations and
257 the environmental exposures⁷. Their action is particularly important for infectious

258 diseases due to the selective constraints that are imposed by the host-pathogen
259 interactions^{8,9}. Literature examples of this in COVID-19 severity includes a *DOCK2*
260 gene variant in East Asians¹⁰, and frequent loss of function variants in *IFNARI* and
261 *IFNAR2* genes in Polynesian and Inuit populations, respectively^{11,12}.

262 Including diverse populations in case-control GWAS studies with unrelated participants
263 usually require a prior classification of individuals in genetically homogeneous groups,
264 which are typically analysed separately to control the population stratification effects¹³.
265 Populations with recent admixture impose an additional challenge to the GWAS due to
266 their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the
267 development of alternative approaches and a careful inspection of results to reduce the
268 false positives due to population structure⁷. In fact, there are benefits in study power
269 from modelling the admixed ancestries either locally, at regional scale in the
270 chromosomes, or globally, across the genome, depending on factors such as the
271 heterogeneity of the risk variant in frequencies or the effects among the ancestry
272 strata¹⁴. Despite the development of novel methods specifically tailored for the analysis
273 of admixed populations¹⁵, the lack of a standardized analysis framework and the
274 difficulties to confidently cluster the admixed individuals into particular genetic groups
275 often leads to their exclusion from GWAS.

276 The Spanish Coalition to Unlock Research on Host Genetics on COVID-19
277 (SCOURGE) recruited COVID-19 patients between March and December 2020 from
278 hospitals across Spain and from March 2020 to July 2021 in Latin-America
279 (<https://www.scourge-covid.org>). A first GWAS of COVID-19 severity among Spanish
280 patients of European descent revealed novel disease loci and explored age and sex
281 varying effects of the genetic factors¹⁶. Here we present the findings of a GWAS meta-
282 analysis in admixed American (AMR) populations, comprising individuals from the

283 SCOURGE Latin-American cohort and the HGI studies, which allowed to identify two
284 novel severe COVID-19 loci, *BAZ2B* and *DDIAS*. Further analyses modelling the
285 admixture from three genetic ancestral components and performing a trans-ethnic meta-
286 analysis led to the identification of an additional risk locus near *CREBBP*. We finally
287 assessed a cross-ancestry polygenic risk score model with variants associated with
288 critical COVID-19.

289 **Results**

290 **Meta-analysis of COVID-19 hospitalization in admixed Americans**

291 *Study cohorts*

292 Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887
293 controls (not hospitalized COVID-19 patients) from Latin-American countries and from
294 recruitments of individuals of Latin-American descent conducted in Spain
295 (Supplementary Table 1). Quality control details and estimation of global genetic
296 inferred ancestry (GIA) (supplementary Figure 1) are described in Methods, whereas
297 clinical and demographic characteristics of patients included in the analysis are shown
298 in Table 1. Summary statistics from the SCOURGE cohort were obtained under a
299 logistic mixed model with the SAIGE model (Methods). Another seven studies
300 participating in the COVID-19 HGI consortium were included in the meta-analysis of
301 COVID-19 hospitalization in admixed Americans (Figure 1).

302 *GWAS meta-analysis*

303 We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as
304 weights for the overlapping markers. The combined GWAS sample size consisted of
305 4,702 admixed AMR hospitalized cases and 68,573 controls.

306 This GWAS meta-analysis revealed genome-wide significant associations at four risk
307 loci (Table 2, Figure 2), two of which (*BAZ2B* and *DDIAS*) were novel discoveries.
308 Variants of these loci were prioritized by positional and expression quantitative trait loci
309 (eQTL) mapping with FUMA, identifying four lead variants linked to other 310 variants
310 and 31 genes (Supplementary Tables 2-4). A gene-based association test revealed a
311 significant association in *BAZ2B* and in previously known COVID-19 risk loci:
312 *LZTFL1*, *XCRI*, *FYCO1*, *CCR9*, and *IFNAR2* (Supplementary Table 5).

313 Located within the gene *BAZ2B*, the sentinel variant rs13003835 is an intronic variant
314 associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20,
315 95% Confidence Interval [CI]=1.12-1.27, $p=3.66 \times 10^{-8}$). This association was not
316 previously reported in any GWAS of COVID-19 published to date. Interestingly,
317 rs13003835 did not reach significance ($p=0.972$) in the COVID-19 HGI trans-ancestry
318 meta-analysis including the five population groups¹. Based on our mapping strategy
319 (see Methods), we also prioritized *PLA2R1*, *LY75*, *WDSUB1*, and *CD302* in this locus.

320 The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic
321 variant located in chromosome 11 within *DDIAS* and associated with risk of COVID-19
322 hospitalization (OR=2.27, 95%CI=1.70-3.04, $p=2.26 \times 10^{-8}$). The *PRCP* gene was an
323 additional prioritized gene at this locus.

324 We also observed a suggestive association with rs2601183 in chromosome 15, which is
325 located between *ZNF774* and *IQGAP1* (allele-G OR=1.20, 95%CI=1.12-1.29,
326 $p=6.11 \times 10^{-8}$, see Supplementary Table 2), which has not yet been reported in any other
327 GWAS of COVID-19 to date. This sentinel variant is in perfect LD ($r^2=1$) with
328 rs601183, an eQTL of *ZNF774* in the lung.

329 The GWAS meta-analysis also pinpointed two significant variants at known loci,
330 *LZTFL1* and *FOXP4*. The SNP rs35731912 was previously associated with COVID-19
331 severity in EUR populations¹⁷, and it was mapped to *LZTFL1*. As for rs2477820, while
332 it is a novel risk variant within gene *FOXP4*, it has a moderate LD ($r^2=0.295$) with
333 rs2496644, which has been linked to COVID-19 hospitalization¹⁸. This is consistent
334 with the effects of LD in tag-SNPs when conducting GWAS in diverse populations.

335 **Functional mapping of novel risk variants**

336 *Bayesian fine mapping*

337 We performed different approaches to narrow down the prioritized loci to a set of most
338 probable genes driving the associations. First, we computed credible sets at the 95%
339 confidence for causal variants and annotated them with VEP and the V2G aggregate
340 scoring (Supplementary Table 6, Supplementary Figure 3). The 95% confidence
341 credible set from the region of chromosome 2 around rs13003835 included 76 variants.
342 However, the approach was unable to converge allocating variants in a 95% confidence
343 credible set for the region in chromosome 11.

344 *Colocalization of eQTLs*

345 To determine if the novel genetic risk loci were associated with gene expression in
346 relevant tissues (whole blood, lung, lymphocytes, and oesophagus mucosa), we
347 computed the posterior probabilities (PP) of colocalization for overlapping variants
348 allocated to the 95% confidence credible set. We used the GTEx v8 tissues as the main
349 expression dataset, although it is important to consider that the eQTL associations were
350 carried out mainly on individuals of EUR ancestries. To confirm the colocalization in
351 other ancestries, we also performed analyses on three expression datasets computed on
352 admixed AMR, leveraging data from individuals with high African GIA, high Native-

353 American ancestry, and from a pooled cohort (Methods). Results are shown in the
354 supplementary Table 7.

355 Five genes (*LY75*, *BAZ2B*, *CD302*, *WDSUB1*, and *PLA2R1*) were the candidates for
356 eQTL colocalization in the associated region in chromosome 2. However, *LY75*
357 emerged as the most likely causal gene for this locus since the colocalization in whole
358 blood was supported with a PP for H4 (PPH4) of 0.941 and with robust results
359 (supplementary Figure 4). Moreover, this also allowed to prioritize rs12692550 as the
360 most probable causal variant for both traits at this locus with a PP_SNP_H4 of 0.74.
361 Colocalization with gene expression data from admixed AMR validated this finding.
362 *LY75* also had evidence of colocalization in lungs (PPH4=0.887) and the esophagus
363 mucosa (PPH4=0.758). However, we could not prioritize a single causal variant in these
364 two other tissues and sensitivity analyses revealed a weak support.

365 *CD302* and *BAZ2B* were the second and third most likely genes that could drive the
366 association, respectively, according to the colocalization evidence. *CD302* was the most
367 probable according to the high AFR genetic ancestries dataset (supplementary Figure
368 5).

369 Despite the chromosome 11 region failing to colocalize with gene expression
370 associations for any of the tissues, the lead variant rs77599934 is in moderate-to-strong
371 LD ($r^2=0.776$) with rs60606421, which is an eQTL associated to a reduced expression
372 of *DDIAS* in the lungs (supplementary Figure 6). The highest PPH4 for *DDIAS* was in
373 the high AFR genetic ancestry expression dataset (0.71).

374 *Transcriptome-wide association study (TWAS)*

375 Five novel genes, namely *SLC25A37*, *SMARCC1*, *CAMP*, *TYW3*, and *S100A12*
376 (supplementary Table 8) were found significantly associated in the cross-tissue TWAS.

377 To our knowledge, these genes have not been reported previously in any COVID-19
378 TWAS or GWAS analyses published to date. In the single tissue analyses, *ATP5O* and
379 *CXCR6* were significantly associated in lungs, *CCR9* was significantly associated in
380 whole blood, and *IFNAR2* and *SLC25A37* were associated in lymphocytes.

381 Likewise, we carried out the TWAS analyses using the models trained in the admixed
382 populations. However, no significant gene-pairs were detected in this case. The 50
383 genes with the lowest p-values are shown in the supplementary Table 9.

384 **Genetic architecture of COVID-19 hospitalization in AMR populations**

385 *Allele frequencies of rs13003835 and rs77599934 across ancestries*

386 Neither rs13003835 (*BAZ2B*) or rs77599934 (*DDIAS*) were significantly associated in
387 the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus,
388 we investigated their allele frequencies (AF) across populations and compared their
389 effect sizes.

390 According to gnomAD v3.1.2, the T allele at rs13003835 (*BAZ2B*) has an AF of 43% in
391 admixed AMR groups while AF is lower in the EUR populations (16%) and in the
392 global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that
393 within the Native-American component, the risk allele T is the major allele, whereas it
394 is the minor allele within the African and European LAI components. These large
395 differences in AF might be the reason underlying the association found in AMR
396 populations. However, when comparing effect sizes between populations, we found that
397 they were in opposite direction between SAS-AMR and EUR-AFR-EAS and that there
398 was a large heterogeneity among them (Figure 3).

399 rs77599934 (*DDIAS*) had an AF of 1.1% for the G allele in the non-hospitalized
400 controls (Table 2), in line with the recorded gnomAD AF of 1% in admixed AMR

401 groups. This variant has potential to be population-specific variant, given the allele
402 frequencies in other population groups such as EUR (0% in Finnish, 0.025% in non-
403 Finnish), EAS (0%) and SAS (0.042%) and its greater effect size over AFR populations
404 (Figure 3). Examining the LAI, the G allele occurs at 1.1% frequency in the African
405 component while it is almost absent in the Native-American and European. Due to its
406 low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population
407 meta-analysis and was only present in the HGI B2 AFR population-specific meta-
408 analysis, precluding the comparison (Figure 3). For this reason, we retrieved the variant
409 with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19
410 HGI cross-population analysis to investigate if it was in moderate-to-strong LD with our
411 sentinel variant. The variant with the smallest p-value was rs75684040 (OR=1.07,
412 95%CI=1.03-1.12, $p=1.84 \times 10^{-3}$). Yet, LD calculations using the 1KGP phase 3 dataset
413 indicated that rs77599934 and rs75684040 were poorly correlated ($r^2=0.11$).

414 *Cross-population meta-analyses*

415 We carried out two cross-ancestry inverse variance-weighted fixed-effects meta-
416 analyses with the admixed AMR GWAS meta-analysis results to evaluate whether the
417 discovered risk loci replicated when considering other population groups. In doing so,
418 we also identified novel cross-population COVID-19 hospitalization risk loci.

419 First, we combined the SCOURGE Latin American GWAS results with the HGI B2
420 ALL analysis (supplementary Table 10). We refer to this analysis as the SC-HGI_{ALL}
421 meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19
422 hospitalization in the last HGI release¹, this study replicated 39 and the association was
423 stronger than in the original study in 29 of those (supplementary Table 11). However,
424 the variant rs13003835 located in *BAZ2B* did not replicate (OR=1.00, 95%CI=0.98-
425 1.03, $p=0.644$).

426 In this cross-ancestry meta-analysis, we replicated two associations that were not found
427 in HGIv7 albeit they were sentinel variants in the latest GenOMICC meta-analysis². We
428 found an association at the *CASC20* locus led by the variant rs2876034 (OR=0.95,
429 95%CI=0.93-0.97, $p=2.83 \times 10^{-8}$). This variant is in strong LD with the sentinel variant
430 of that study (rs2326788, $r^2=0.92$), which was associated with critical COVID-19².
431 Besides, this meta-analysis identified the variant rs66833742 near *ZBTB7A* associated
432 with COVID-19 hospitalization (OR=0.94, 95%CI=0.92-0.96, $p=2.50 \times 10^{-8}$). Notably,
433 rs66833742 or its perfect proxy rs67602344 ($r^2=1$) are also associated with upregulation
434 of *ZBTB7A* in whole blood and in esophagus mucosa. This variant was previously
435 associated with COVID-19 hospitalization².

436 In a second analysis, we also explored the associations across the defined admixed
437 AMR, EUR, and AFR ancestral sources by combining through meta-analysis the
438 SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and
439 admixed AMR, and excluding those from EAS and SAS (Supplementary Table 12). We
440 refer to this as the SC-HGI_{3POP} meta-analysis. The association at rs13003835 (*BAZZ2B*,
441 OR=1.01, 95%CI=0.98-1.03, $p=0.605$) was not replicated and rs77599934 near *DDIAS*
442 could not be assessed, although the association at the *ZBTB7A* locus was confirmed
443 (rs66833742, OR=0.94, 95%CI=0.92-0.96, $p=1.89 \times 10^{-8}$). The variant rs76564172
444 located near *CREBBP* also reached statistical significance (OR=1.31, 95% CI=1.25-
445 1.38, $p=9.64 \times 10^{-9}$). The sentinel variant of the region linked to *CREBBP* (in the trans-
446 ancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary
447 Table 6) and colocalization with eQTLs under the GTEx v8 MASHR models in lungs,
448 esophagus mucosa, whole blood, and transformed lymphocytes. Eight variants were
449 included in the credible set for the region in chromosome 16 (meta-analysis SC-
450 HGI_{3POP}), although *CREBBP* did not colocalize in any of the tissues.

451 **Polygenic risk score models**

452 Using the 49 variants associated with disease severity that are shared across populations
453 according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its
454 generalizability in the admixed AMR (Supplementary Table 13). First, we calculated
455 the PGS for the SCOURGE Latin Americans and explored the association with
456 COVID-19 hospitalization under a logistic regression model. The PGS model was
457 associated with a 1.48-fold increase in COVID-19 hospitalization risk per every PGS
458 standard deviation. It also contributed to explain a slightly larger variance ($R^2=1.07\%$)
459 than the baseline model.

460 Subsequently, we divided the individuals into PGS deciles and percentiles to assess
461 their risk stratification. The median percentile among controls was 40, while in cases it
462 was 63. Those in the top PGS decile exhibited a 5.90-fold (95% CI=3.29-10.60,
463 $p=2.79 \times 10^{-9}$) greater risk compared to individuals in the lowest decile, whereas the
464 effects for the rest of the comparisons were much milder.

465 We also examined the distribution of PGS scores across a 5-level severity scale to
466 further determine if there was any correspondence between clinical severity and genetic
467 risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas
468 higher median scores were observed in the moderate, severe, and critical patients
469 (Figure 4). We fitted a multinomial model using the asymptomatic class as reference
470 and calculated the OR for each category (Supplementary Table 13), observing that the
471 disease genetic risk was similar among asymptomatic, mild, and moderate patients.
472 Given that the PGS was built with variants associated with critical disease and/or
473 hospitalization and that the categories severe and critical correspond to hospitalized
474 patients, these results underscore the ability of cross-ancestry PGS for risk stratification
475 even in an admixed population.

476 Finally, we incorporated the novel lead SNPs from our AMR meta-analysis
477 (rs13003835, rs2477820, and rs77599934) into the PGS model. Their inclusion in the
478 model contributed to explain a larger variance ($R^2=1.74\%$) than the model without
479 them. This result, however, should be taken with caution given the risk of overfitting
480 due to the use of the same subjects both for the derivation and testing of the variants.

481

482 **DISCUSSION**

483 We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in
484 admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely
485 shared among populations, trans-ancestry meta-analyses on this disease have primarily
486 included EUR samples. This dominance of GWAS in Europeans, and the subsequent
487 bias in sample sizes, can mask population-specific genetic risks (i.e., variants that are
488 monomorphic in some populations) or be less powered to detect risk variants having
489 higher allele frequencies in population groups other than Europeans. In this sense, after
490 combining data from admixed AMR patients, we found two risk loci which are first
491 discovered in a GWAS of Latin-American populations. Interestingly, the sentinel
492 variant rs77599934 in the *DDIAS* gene is a rare coding variant (~1% for allele G) with a
493 large effect on COVID-19 hospitalization that is nearly monomorphic in most of the
494 other populations. This has likely led to its exclusion from the cross-populations meta-
495 analyses conducted to date, remaining undetectable.

496 Fine mapping of the region harbouring *DDIAS* did not reveal further information about
497 which gene could be the more prone to be causal, or about the functional consequences
498 of the risk variant. However, *DDIAS*, known as damage-induced apoptosis suppressor
499 gene, is itself a plausible candidate gene. It has been linked to DNA damage repair

500 mechanisms: research showed that depletion of *DDIAS* led to an increase of ATM
501 phosphorylation and the formation of p53-binding protein (53BP1) foci, a known
502 biomarker of DNA double-strand breaks, suggesting a potential role in double-strand
503 break repair¹⁹. Similarly, elevated levels of phosphorylated nuclear histone 2AX γ were
504 detected after knocking down *DDIAS*, further emphasizing its role in DNA damage²⁰.
505 Interestingly, a study found that the infection by SARS-CoV-2 also triggered the
506 phosphorylation of the ATM kinase and inhibited repair mechanisms, causing the
507 accumulation of DNA damage²¹. This same study reported the activation of the pro-
508 inflammatory pathway p38/MAPK by the virus, which was as well prompted after
509 knocking-down *DDIAS*²⁰.

510 Regarding lung function, the role of *DDIAS* in lung cancer has been widely studied. It
511 has been proposed as a potential biomarker for lung cancer after finding that it interacts
512 with STAT3 in lung cancer cells, regulating IL-6^{22,23} and thus mediating inflammatory
513 processes. Furthermore, another study determined that its blockade inhibited lung
514 cancer cell growth²⁰. The sentinel variant was in strong LD with an eQTL that reduced
515 gene expression of *DDIAS* in lung, and our findings suggest that *DDIAS* gene may be
516 indeed involved in viral response. Hence, one reasonable hypothesis is that reduced
517 expression of *DDIAS* could potentially facilitate SARS-CoV-2 infection through the
518 downregulation of pathways involved in DNA repairment and inflammation. Another
519 prioritized gene from this region was *PRCP*, an angiotensinase that has been linked to
520 hypertension and for which a hypothesis on its role on COVID-19 progression has been
521 raised^{24,25}.

522 The risk region found in chromosome 2 prioritized more than one gene. The lead variant
523 rs13003835 is located within *BAZ2B*. *BAZ2B* encodes one of the regulatory subunits of
524 the Imitation switch (ISWI) chromatin remodelers²⁶ constituting the BRF-1/BRF-5

525 complexes with SMARCA1 and SMARCA5, respectively, and the association signal
526 colocalized with eQTLs in whole blood. The gene *LY75* (encoding the lymphocyte
527 antigen 75) also colocalized with eQTLs in whole blood, esophagus mucosa, and lung
528 tissues. Lymphocyte antigen 75 is involved in immune processes through antigen
529 presentation in dendritic cells and endocytosis²⁷, and has been associated with
530 inflammatory diseases, representing also a compelling candidate for the region.
531 Increased expression of *LY75* has been detected within hours after the infection by
532 SARS-CoV-2^{28,29}. Lastly, the signal of *CD302* colocalized in individuals with high
533 AFR ancestral admixture in whole blood. This gene is located in the vicinity of *LY75*
534 and both conform the readthrough *LY75-CD302*. It is worth noting that differences in
535 AF for this variant suggest that analyses in AMR populations might be more powered to
536 detect the association, supporting the necessity of population-specific studies.

537 A third novel risk region was observed in chromosome 15, between the genes *IQGAP1*
538 and *ZNF774*, although not reaching genome-wide significance.

539 Secondary analyses revealed five TWAS-associated genes, some of which have been
540 already linked to severe COVID-19. In a comprehensive multi-tissue gene expression
541 profiling study³⁰, decreased expression of *CAMP* and *S100A8/S100A9* genes in COVID-
542 19 severe patients was observed, while another study detected the upregulation of
543 *SCL25A37* among severe COVID-19 patients³¹. *SMARCC1* is a subunit of the SWI/SNF
544 chromatin remodelling complex that has been identified as pro-viral for SARS-CoV-2
545 and other coronavirus strains through a genome-wide screen³². This complex is crucial
546 for *ACE2* expression and the viral entry in the cell³³.

547 To explore the genetic architecture of the trait among admixed AMR populations, we
548 performed two cross-ancestry meta-analyses including the SCOURGE Latin-American
549 cohort GWAS findings. We found that the two novel risk variants did not associate with

550 COVID-19 hospitalization outside the population-specific meta-analysis, highlighting
551 the importance of complementing trans-ancestry meta-analyses with group-specific
552 analyses. Notably, this analysis did not replicate the association at the *DSTYK* locus,
553 which was associated with severe COVID-19 in Brazilian individuals with higher
554 European admixture³⁴. This lack of replication supports the initial hypothesis of that
555 study suggesting that the risk haplotype derived from European populations, as we have
556 reduced the weight of this ancestral contribution in our study by excluding those
557 individuals.

558 Moreover, these cross-ancestry meta-analyses pointed to three loci that were not
559 genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at *CREBBP*,
560 and two loci at *ZBTB7A* and *CASC20* that were reported in another meta-analysis.
561 *CREBBP* and *ZBTB7A* achieved a stronger significance when considering only EUR,
562 AFR, and admixed AMR GIA groups. According to a recent study, elevated levels of
563 the *ZBTB7A* gene promote a quasi-homeostatic state between coronaviruses and host
564 cells, preventing cell death by regulating oxidative stress pathways³⁵. This gene is
565 involved in several signalling pathways, such as B and T cell differentiation³⁶. On a
566 separate note, *CREBBP* encodes the CREB binding protein (CBP), involved in
567 transcription activation, that is known to positively regulate the type I interferon
568 response through virus-induced phosphorylation of IRF-3³⁷. Besides, the CREBP/CBP
569 interaction has been implicated in SARS-CoV-2 infection³⁸ via the cAMP/PKA
570 pathway. In fact, cells with suppressed *CREBBP* gene expression exhibit reduced
571 replication of the so called Delta and Omicron SARS-CoV-2 variants³⁸.

572 The cross-population PGS model effectively stratified individuals based on their genetic
573 risk and demonstrated consistency with the clinical severity classification of the
574 patients. The inclusion of the new variants in the PGS model slightly improved the

575 predictive value of the PGS. However, it is important to confirm this last finding in an
576 external admixed AMR cohort to address potential overfitting arising from using the
577 same individuals both for the discovery of the associations and for testing the model.

578 This study is subject to limitations, mostly concerning the sample recruitment and
579 composition. The SCOURGE Latino-American sample size is small and the GWAS is
580 underpowered. Another limitation is the difference in case-control recruitment across
581 sampling regions that, yet controlled for, may reduce the ability to observe significant
582 associations driven by different compositions of the populations. In this sense, the
583 identified risk loci might not replicate in a cohort lacking any of the parental population
584 sources from the three-way admixture. Likewise, we could not explicitly control for
585 socio-environmental factors that could have affected COVID-19 spread and
586 hospitalization rates, although genetic principal components are known to capture non-
587 genetic factors. Finally, we must acknowledge the lack of a replication cohort. We have
588 used all the available GWAS data for COVID-19 hospitalization in admixed AMR in
589 this meta-analysis due to the low number of studies conducted. Therefore, we had no
590 studies to replicate or validate the results. These concerns may be addressed in the
591 future by including more AMR GWAS studies in the meta-analysis, both by involving
592 diverse populations in study designs and by supporting research from countries in Latin-
593 America.

594 This study provides novel insights into the genetic basis of COVID-19 severity,
595 emphasizing the importance of considering host genetic factors through using non-
596 European populations, especially of admixed sources. Such complementary efforts can
597 pin down new variants and increase our knowledge on the host genetic factors of severe
598 COVID-19.

599 **Materials and methods**

600 **GWAS in Latin Americans from SCOURGE**

601 *The SCOURGE Latin American cohort*

602 A total of 3,729 of COVID-19 positive cases were recruited across five countries from
603 Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating
604 centres (supplementary Table 1) from March 2020 to July 2021. In addition, we
605 included 1,082 COVID-19 positive individuals recruited between March and December
606 2020 in Spain who either had evidence of origin from a Latin American country or
607 showed inferred genetic admixture between AMR, EUR, and AFR (with < 0.05%
608 SAS/EAS). These individuals were excluded from a previous SCOURGE study that
609 focused on participants with European genetic ancestries¹⁶. We used hospitalization as a
610 proxy for disease severity and defined as cases those COVID-19 positive patients that
611 underwent hospitalization as a consequence of the infection and used as controls those
612 that did not need hospitalization due to COVID-19.

613 Samples and data were collected with informed consent after the approval of the Ethics
614 and Scientific Committees from the participating centres and by the Galician Ethics
615 Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City), was
616 approved by of the National Committee of Clinical Research, from Instituto Mexicano del
617 Seguro Social, Mexico (protocol R-2020-785-082).

618 Samples and data were processed following normalized procedures. The REDCap
619 electronic data capture tool^{39,40}, hosted at Centro de Investigación Biomédica en Red
620 (CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage
621 demographic, epidemiological, and clinical variables. Subjects were diagnosed for
622 COVID-19 based on quantitative PCR tests (79.3%), or according to clinical (2.2%) or
623 laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%).

624 *SNP array genotyping*

625 Genomic DNA was obtained from peripheral blood and isolated using the Chemagic
626 DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the
627 manufacturer's recommendations.

628 Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher
629 Scientific) following the manufacturer's instructions in the Santiago de Compostela
630 Node of the National Genotyping Center (CeGen-ISCI3; <http://www.usc.es/cegen>).
631 This array contains probes for genotyping a total of 757,836 SNPs. Clustering and
632 genotype calling were performed using the Axiom Analysis Suite v4.0.3.3 software.

633 *Quality control steps and variant imputation*

634 A quality control (QC) procedure using PLINK 1.9⁴¹ was applied to both samples and
635 the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) <1%,
636 a call rate <98%, and markers strongly deviating from Hardy-Weinberg equilibrium
637 expectations ($p < 1 \times 10^{-6}$) with mid-p adjustment. We also explored the excess of
638 heterozygosity to discard potential cross-sample contaminations. Samples missing >2%
639 of the variants were filtered out. Subsequently, we kept the autosomal SNPs and
640 removed high LD regions and conducted LD-pruning (windows of 1,000 SNPs, with
641 step size of 80 and r^2 threshold of 0.1) to assess kinship and estimate the global
642 ancestral proportions. Kinship was evaluated based on IBD values, removing one
643 individual from each pair with $PI_HAT > 0.25$ that showed a Z0, Z1, and Z2 coherent
644 pattern (according to the theoretical expected values for each relatedness level). Genetic
645 principal components (PCs) were calculated with PLINK with the subset of LD pruned
646 variants.

647 Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using
648 the TOPMed Imputation Server and variants with $Rsq < 0.3$ or with $MAF < 1\%$ were
649 filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included
650 in the analyses.

651 *Genetic admixture estimation*

652 Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used
653 reference individuals, was estimated with the ADMIXTURE⁴² v1.3 software following
654 a two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African
655 (AFR) samples from The 1000 Genomes Project (1KGP)⁴³ and merged them with the
656 79 Native American (AMR) samples from Mao et al.⁴⁴ keeping the biallelic SNPs. LD-
657 pruned variants were selected from this merge using the same parameters as in the QC.
658 We then run an unsupervised analysis with $K=3$ to redefine and homogenize the clusters
659 and to compose a refined reference for the analyses, by applying a threshold of $\geq 95\%$
660 of belonging to a particular cluster. As a result of this, 20 AFR, 18 EUR, and 38 AMR
661 individuals were removed. The same LD-pruned variants data from the remaining
662 individuals were merged with the SCOURGE Latin American cohort to perform a
663 supervised clustering and estimated admixture proportions. A total of 471 samples from
664 the SCOURGE cohort with $>80\%$ estimated European GIA were removed to reduce the
665 weight of the European ancestral component, leaving a total of 3,512 admixed
666 American (AMR) subjects for downstream analyses.

667 *Association analysis*

668 Results for the SCOURGE Latin Americans GWAS were obtained testing for COVID-
669 19 hospitalization as a surrogate of severity. To accommodate the continuum of GIA in
670 the cohort, we opted for a joint testing of all the individuals as a single study using a

671 mixed regression model, as this approach has demonstrated a greater power and to
672 sufficiently control population structure⁴⁵. The SCOURGE cohort consisted of 3,512
673 COVID-19 positive patients: cases (n=1,625) were defined as hospitalized COVID-19
674 patients and controls (n=1,887) as non-hospitalized COVID-19 positive patients.

675 Logistic mixed regression models were fitted using the SAIGEgds⁴⁶ package in R,
676 which implements the two-step mixed SAIGE⁴⁷ model methodology and the SPA test.
677 Baseline covariables included sex, age, and the first 10 PCs. To account for a potential
678 heterogeneity in the recruitment and hospitalization criteria across the participating
679 countries, we adjusted the models by groups of the recruitment areas classified in six
680 categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. This dataset has
681 not been used in any previously GWAS of COVID-19 published to date.

682 **Meta-analysis of Latin-American populations**

683 The results of the SCOURGE Latin American cohort were meta-analyzed with the
684 AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI
685 freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from
686 the public repository (April 8, 2022: <https://www.covid19hg.org/results/r7/>), summing
687 up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2
688 phenotype definition because it offered more power and the presence of population
689 controls not ascertained for COVID-19 does not have a drastic impact in the association
690 results.

691 The meta-analysis was performed using an inverse-variance weighting method in
692 METAL⁴⁸. Average allele frequency was calculated and variants with low imputation
693 quality ($R_{sq} < 0.3$) were filtered out, leaving 10,121,172 variants for meta-analysis.

694 Heterogeneity between studies was evaluated with the Cochran's-Q test. The inflation
695 of results was assessed based on a genomic control (λ).

696 **Definition of the genetic risk loci and putative functional impact**

697 *Definition of lead variant and novel loci*

698 To define the lead variants in the loci that were genome-wide significant, an LD-
699 clumping was performed on the meta-analysis data using a threshold $p\text{-value} < 5 \times 10^{-8}$,
700 clump distance = 1500 kb, independence set at a threshold $r^2 = 0.1$ and used the
701 SCOURGE cohort genotype data as LD reference panel. Independent loci were deemed
702 as a novel finding if they met the following criteria: 1) $p\text{-value} < 5 \times 10^{-8}$ in the meta-
703 analysis and $p\text{-value} > 5 \times 10^{-8}$ in the HGI B2 ALL meta-analysis or in the HGI B2 AMR
704 and AFR and EUR analyses when considered by separate; 2) Cochran's Q-test for
705 heterogeneity of effects is $< 0.05/N_{\text{loci}}$, where N_{loci} is the number of independent variants
706 with $p < 5 \times 10^{-8}$; and 3) the nearest gene has not been previously described in the latest
707 HGv7 update.

708 *Annotation and initial mapping*

709 Functional annotation was done with FUMA⁴⁹ for those variants with a $p\text{-value} < 5 \times 10^{-8}$
710 or in moderate-to-strong LD ($r^2 > 0.6$) with the lead variants, where the LD was
711 calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing
712 LD-blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB
713 v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA⁴⁹.
714 Gene-based analysis was also performed using MAGMA⁵⁰ as implemented in FUMA,
715 under the SNP-wide mean model using the 1KGP AMR reference panel. Significance
716 was set at a threshold $p < 2.66 \times 10^{-6}$ (which assumes that variants can be mapped to a total
717 of 18,817 genes).

718 FUMA allowed us to perform an initial gene mapping by two approaches: (1) positional
719 mapping, which assigns variants to genes by physical distance using 10-kb windows;
720 and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes,
721 and oesophagus mucosa tissues, establishing a False Discovery Rate (FDR) of 0.05 to
722 declare significance for variant-gene pairs.

723 Subsequently, to assign the variants to the most likely gene driving the association, we
724 refined the candidate genes by fine mapping the discovered regions and implementing
725 functional mapping.

726 To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel
727 findings were calculated on the results from each of the three meta-analyses to identify a
728 subset of variants most likely containing the causal variant at 95% confidence level,
729 assuming that there is a single causal variant and that it has been tested. We used
730 *corrcoverage* (<https://cran.rstudio.com/web/packages/corrcoverage/index.html>) for R to
731 calculate the posterior probabilities of the variant being causal for all variants with an
732 $r^2 > 0.1$ with the leading SNP and within 1 Mb except for the novel variant in
733 chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the
734 credible set until the sum of the posterior probabilities was ≥ 0.95 . VEP
735 (<https://www.ensembl.org/info/docs/tools/vep/index.html>) and the V2G aggregate
736 scoring from Open Targets Genetics (<https://genetics.opentargets.org>) were used to
737 annotate the biological function of the variants contained in the fine-mapped credible
738 sets

739 *Colocalization analysis*

740 We also conducted colocalization analyses to identify the putative causal genes that
741 could act through the regulation of gene expression. FUMA's eQTL mapping enabled

742 the identification of genes whose expression was associated with the variants in whole
743 blood, lungs, lymphocytes, and oesophagus mucosa tissues. We combined this
744 information with the VEP and V2G aggregate scoring to prioritize genes. For the fine-
745 mapping regions, we included the variants within the calculated credible sets. In the
746 cases where the fine mapping was unsuccessful, we considered variants within a 0.2 Mb
747 window of the lead variant.

748 For each prioritized gene, we then run COLOC⁵¹ to assess the evidence of
749 colocalization between association signals and the eQTLs in each tissue, when at least
750 one variant overlapped between them. COLOC estimates the posterior probability of
751 two traits sharing the same causal variant in a locus. Prior probabilities of a variant
752 being associated to COVID-19 phenotype (p1) and gene expression (p2) were set at
753 1×10^{-4} , while pp2 was set at 1×10^{-6} as they are robust thresholds⁵². The posterior
754 probability of colocalization (PP4) > 0.75 and a ratio PP4/PP3 > 3 were used as the
755 criteria to support evidence of colocalization. Additionally, a threshold of PP4.SNP > 0.5
756 was chosen for causal variant prioritization. In cases where colocalization of a single
757 variant failed, we computed the 95% credible sets. The eQTL data was retrieved from
758 GTEx v8 and only significant variant-gene pairs were considered in the analyses.

759 Colocalization in whole-blood was also performed using the recent published gene
760 expression datasets derived from a cohort of African Americans, Puerto Ricans, and
761 Mexican Americans (GALA II-SAGE)⁵³. We used the results from the pooled cohort
762 for the three discovered loci, and from the AFRHp5 (African genetic ancestry > 50%)
763 and IAMHp5 (Native American genetic ancestry > 50%) cohorts for the risk loci in
764 chromosomes 2 and 11. Results are shown in the Supplementary Table 10.

765 Sensitivity plots are shown in supplementary Figures 4 and 5.

766 **Transcription-wide association studies**

767 Transcriptome-wide association studies (TWAS) were conducted using the pretrained
768 prediction models with MASHR-computed effect sizes on GTEx v8 datasets^{54,55}.
769 Results from the Latin-American meta-analysis were harmonized and integrated with
770 the prediction models through S-PrediXcan⁵⁶ for lungs, whole blood, lymphocytes and
771 oesophagus mucosa tissues. Statistical significance was set at $p\text{-value} < 0.05$ divided by
772 the number of genes that were tested for each tissue. Subsequently, we leveraged results
773 for all 49 tissues and run a multi-tissue TWAS to improve power for association, as
774 demonstrated recently⁵⁷. TWAS was also conducted with the MASHR models for
775 whole-blood in the pooled admixed AMR from the GALA and SAGE studies⁵³.

776 **Cross-population meta-analyses**

777 We conducted two additional meta-analyses to investigate the ability of combining
778 populations to replicate our discovered risk loci. This methodology enabled the
779 comparison of effects and the significance of associations in the novel risk loci between
780 the results from analyses that included or excluded other population groups.

781 The first meta-analysis comprised the five populations analysed within HGI (B2-ALL).
782 Additionally, to evaluate the three GIA components within the SCOURGE Latin-
783 American cohort⁵⁸, we conducted a meta-analysis of the admixed AMR, EUR, and AFR
784 cohorts (B2). All summary statistics were retrieved from the HGI repository. We
785 applied the same meta-analysis methodology and filters as in the admixed AMR meta-
786 analysis. Novel variants from these meta-analyses were fine-mapped and colocalized
787 with gene expression.

788 **Cross-population Polygenic Risk Score**

789 A polygenic risk score (PGS) for critical COVID-19 was derived combining the
790 variants associated with hospitalization or disease severity that have been discovered to
791 date. We curated a list of lead variants that were: 1) associated to either severe disease
792 or hospitalization in the latest HGIv7 release¹ (using the hospitalization weights); or 2)
793 associated to severe disease in the latest GenOMICC meta-analysis² that were not
794 reported in the latest HGI release. A total of 49 markers were used in the PGS model
795 (see supplementary Table 13) since two variants were absent from our study.

796 Scores were calculated and normalized for the SCOURGE Latin-American cohort with
797 PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization
798 (COVID-19 positive that were hospitalized vs. COVID-19 positive that did not
799 necessitate hospital admission) by fitting a logistic regression model. Prediction
800 accuracy for the PGS was assessed by performing 500 bootstrap resamples of the
801 increase in the pseudo-R-squared. We also divided the sample in deciles and percentiles
802 to assess risk stratification. The models were fit for the dependent variable adjusting for
803 sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR cohort) with
804 and without the PGS, and the partial pseudo-R² was computed and averaged among the
805 resamples.

806 A clinical severity scale was used in a multinomial regression model to further evaluate
807 the power of this cross-ancestry PGS for risk stratification. This severity strata were
808 defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without
809 pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary
810 infiltrates affecting <50% of the lungs or need of supplemental oxygen therapy; 3)
811 severe disease, that is with hospital admission and PaO₂<65 mmHg or SaO₂<90%,
812 PaO₂/FiO₂<300, SaO₂/FiO₂<440, dyspnea, respiratory frequency≥22 bpm, and
813 infiltrates affecting >50% of the lungs; and 4) critical disease, that is with an admission

814 to the ICU or need of mechanical ventilation (invasive or non-invasive). We also
815 included the novel risk variants as predictors alongside the PRS to determine if they
816 provided increased prediction ability.

817 **Data availability**

818 Summary statistics from the SCOURGE Latin-American GWAS will be available at
819 <https://github.com/CIBERER/Scourge-COVID19>.

820

821 **Funding**

822 Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B.,
823 COV20_00181 to C.A., COV20_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.);
824 European Union (ERDF) ‘A way of making Europe’. Fundación Amancio Ortega,
825 Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association
826 (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación
827 (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140
828 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.)
829 and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57
830 to C.F.).

831 SD-DA was supported by a Xunta de Galicia predoctoral fellowship.

832 **Author contributions**

833 Study design: RC, AC, CF. Data collection: SCOURGE cohort group. Data analysis:
834 SD-DA, RC, ADL, CF, JML-S. Interpretation: SD-DA, RC, ADL. Drafting of the
835 manuscript: SD-DA, RC, ADL, CF, AR-M, AC. Critical revision of the manuscript:

836 SD-DA, RC, ADL, AC, CF, JAR, AR-M, PL. Approval of the final version of the
837 publication: all co-authors.

838 **Acknowledgements**

839 The contribution of the Centro Nacional de Genotipado (CEGEN), and Centro de
840 Supercomputación de Galicia (CESGA) for funding this project by providing
841 supercomputing infrastructures, is also acknowledged. Authors are also particularly
842 grateful for the supply of material and the collaboration of patients, health professionals
843 from participating centers and biobanks. Namely Biobanc-Mur, and biobanks of the
844 Complejo Hospitalario Universitario de A Coruña, Complejo Hospitalario
845 Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital
846 Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria
847 Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS
848 Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón,
849 Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN.

850

851 **References**

- 852 1. Initiative, T. C.-19 H. G. & Ganna, A. A second update on mapping the human genetic
853 architecture of COVID-19. 2022.12.24.22283874 Preprint at
854 <https://doi.org/10.1101/2022.12.24.22283874> (2023).
- 855 2. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 |
856 Nature. <https://www.nature.com/articles/s41586-023-06034-3>.
- 857 3. Niemi, M. E. K. *et al.* Mapping the human genetic architecture of COVID-19. *Nature*
858 **600**, 472–477 (2021).
- 859 4. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164
860 (2016).
- 861 5. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
862 Studies. *Cell* **177**, 26–31 (2019).

- 863 6. Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and
864 challenges of mapping in diverse populations. *Genome Med.* **6**, 91 (2014).
- 865 7. Rosenberg, N. A. *et al.* Genome-wide association studies in diverse populations. *Nat.*
866 *Rev. Genet.* **11**, 356–366 (2010).
- 867 8. Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: new tools,
868 insights and translational opportunities. *Nat. Rev. Genet.* **22**, 137–153 (2021).
- 869 9. Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious
870 disease in human populations. *Nat. Rev. Genet.* **15**, 379–393 (2014).
- 871 10. Namkoong, H. *et al.* DOCK2 is involved in the host genetics and biology of severe
872 COVID-19. *Nature* **609**, 754–760 (2022).
- 873 11. Bastard, P. *et al.* A loss-of-function IFNAR1 allele in Polynesia underlies severe viral
874 diseases in homozygotes. *J. Exp. Med.* **219**, e20220028 (2022).
- 875 12. Duncan, C. J. A. *et al.* Life-threatening viral disease in a novel form of autosomal
876 recessive IFNAR2 deficiency in the Arctic. *J. Exp. Med.* **219**, e20212427 (2022).
- 877 13. Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse
878 Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589–603
879 (2019).
- 880 14. Mester, R. *et al.* Impact of cross-ancestry genetic architecture on GWAS in admixed
881 populations. 2023.01.20.524946 Preprint at <https://doi.org/10.1101/2023.01.20.524946>
882 (2023).
- 883 15. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and
884 to boost power | Nature Genetics. <https://www.nature.com/articles/s41588-020-00766-y>.
- 885 16. Cruz, R. *et al.* Novel genes and sex differences in COVID-19 severity. *Hum. Mol. Genet.*
886 **31**, 3789–3806 (2022).
- 887 17. Degenhardt, F. *et al.* Detailed stratified GWAS analysis for severe COVID-19 in four
888 European populations. *Hum. Mol. Genet.* **31**, 3945–3966 (2022).
- 889 18. Whole-genome sequencing reveals host factors underlying critical COVID-19 | Nature.
890 <https://www.nature.com/articles/s41586-022-04576-6>.
- 891 19. Evolution-based screening enables genome-wide prioritization and discovery of DNA
892 repair genes | PNAS. <https://www.pnas.org/doi/full/10.1073/pnas.1906559116>.
- 893 20. Human Noxin is an anti-apoptotic protein in response to DNA damage of A549
894 non-small cell lung carcinoma - Won - 2014 - International Journal of Cancer - Wiley Online
895 Library. <https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600>.
- 896 21. Gioia, U. *et al.* SARS-CoV-2 infection induces DNA damage, through CHK1 degradation
897 and impaired 53BP1 recruitment, and cellular senescence. *Nat. Cell Biol.* **25**, 550–564 (2023).
- 898 22. Im, J.-Y. *et al.* DDIAS promotes STAT3 activation by preventing STAT3 recruitment to
899 PTPRM in lung cancer cells. *Oncogenesis* **9**, 1–11 (2020).

- 900 23. Im, J.-Y., Kang, M.-J., Kim, B.-K. & Won, M. DDIAS, DNA damage-induced apoptosis
901 suppressor, is a potential therapeutic target in cancer. *Exp. Mol. Med.* 1–7 (2023)
902 doi:10.1038/s12276-023-00974-6.
- 903 24. Angeli, F. *et al.* The spike effect of acute respiratory syndrome coronavirus 2 and
904 coronavirus disease 2019 vaccines on blood pressure. *Eur. J. Intern. Med.* **109**, 12–21 (2023).
- 905 25. Silva-Aguiar, R. P. *et al.* Role of the renin-angiotensin system in the development of
906 severe COVID-19 in hypertensive patients. *Am. J. Physiol.-Lung Cell. Mol. Physiol.* **319**, L596–
907 L602 (2020).
- 908 26. Li, Y. *et al.* The emerging role of ISWI chromatin remodeling complexes in cancer. *J.*
909 *Exp. Clin. Cancer Res.* **40**, 346 (2021).
- 910 27. The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance
911 Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal
912 Compartments | Journal of Cell Biology | Rockefeller University Press.
913 [https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-](https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-Dec)
914 Dec.
- 915 28. Sims, A. C. *et al.* Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear
916 Import Block Enhances Host Transcription in Human Lung Cells. *J. Virol.* **87**, 3885–3902 (2013).
- 917 29. A Network Integration Approach to Predict Conserved Regulators Related to
918 Pathogenicity of Influenza and SARS-CoV Respiratory Viruses | PLOS ONE.
919 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374>.
- 920 30. Gómez-Carballa, A. *et al.* A multi-tissue study of immune gene expression profiling
921 highlights the key role of the nasal epithelium in COVID-19 severity. *Environ. Res.* **210**, 112890
922 (2022).
- 923 31. Policard, M., Jain, S., Rego, S. & Dakshanamurthy, S. Immune characterization and
924 profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-
925 CoV-2 oncogenesis mechanism. *Virus Res.* **301**, 198464 (2021).
- 926 32. Wei, J. *et al.* Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2
927 Infection. *Cell* **184**, 76-91.e13 (2021).
- 928 33. Wei, J. *et al.* Pharmacological disruption of mSWI/SNF complex activity restricts SARS-
929 CoV-2 infection. *Nat. Genet.* **55**, 471–483 (2023).
- 930 34. Pereira, A. C. *et al.* Genetic risk factors and COVID-19 severity in Brazil: results from
931 BRACOVID study. *Hum. Mol. Genet.* **31**, 3021–3031 (2022).
- 932 35. Zhu, X. *et al.* ZBTB7A promotes virus-host homeostasis during human coronavirus 229E
933 infection. *Cell Rep.* **41**, 111540 (2022).
- 934 36. Gupta, S. *et al.* Emerging role of ZBTB7A as an oncogenic driver and transcriptional
935 repressor. *Cancer Lett.* **483**, 22–34 (2020).
- 936 37. Yoneyama, M. *et al.* Direct triggering of the type I interferon system by virus infection:
937 activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO J.* **17**, 1087–
938 1095 (1998).

- 939 38. Yang, Q. *et al.* SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-
940 dependent pathways. *J. Med. Virol.* **95**, e28383 (2023).
- 941 39. Harris, P. A. *et al.* Research electronic data capture (REDCap)—A metadata-driven
942 methodology and workflow process for providing translational research informatics support. *J.*
943 *Biomed. Inform.* **42**, 377–381 (2009).
- 944 40. Harris, P. A. *et al.* The REDCap consortium: Building an international community of
945 software platform partners. *J. Biomed. Inform.* **95**, 103208 (2019).
- 946 41. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-
947 Based Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
- 948 42. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in
949 unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).
- 950 43. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68–74
951 (2015).
- 952 44. Mao, X. *et al.* A Genomewide Admixture Mapping Panel for Hispanic/Latino
953 Populations. *Am. J. Hum. Genet.* **80**, 1171–1178 (2007).
- 954 45. Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
955 complex traits. *Nature* **570**, 514–518 (2019).
- 956 46. Zheng, X. & Davis, J. W. SAIGEgds—an efficient statistical tool for large-scale PheWAS
957 with mixed models. *Bioinformatics* **37**, 728–730 (2021).
- 958 47. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample
959 relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
- 960 48. METAL: fast and efficient meta-analysis of genomewide association scans |
961 Bioinformatics | Oxford Academic.
962 <https://academic.oup.com/bioinformatics/article/26/17/2190/198154>.
- 963 49. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
964 annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
- 965 50. MAGMA: Generalized Gene-Set Analysis of GWAS Data | PLOS Computational Biology.
966 <https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219>.
- 967 51. Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic
968 Association Studies Using Summary Statistics. *PLOS Genet.* **10**, e1004383 (2014).
- 969 52. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
970 colocalisation analyses. *PLOS Genet.* **16**, e1008720 (2020).
- 971 53. Kachuri, L. *et al.* Gene expression in African Americans, Puerto Ricans and Mexican
972 Americans reveals ancestry-specific patterns of genetic architecture. *Nat. Genet.* **55**, 952–963
973 (2023).
- 974 54. Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at
975 GWAS loci. *Genome Biol.* **22**, 49 (2021).
- 976 55. Barbeira, A. N. *et al.* GWAS and GTEx QTL integration. (2019)
977 doi:10.5281/zenodo.3518299.

978 56. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
 979 expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).

980 57. Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues
 981 improves association detection. *PLoS Genet.* **15**, e1007889 (2019).

982 58. Genome-wide patterns of population structure and admixture among Hispanic/Latino
 983 populations | PNAS. [https://www.pnas.org/doi/10.1073/pnas.0914618107?url_ver=Z39.88-](https://www.pnas.org/doi/10.1073/pnas.0914618107?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)
 984 [2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed.](https://www.pnas.org/doi/10.1073/pnas.0914618107?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed)

985

986

987 Table 1. Demographic characteristics of the SCOURGE Latin-American cohort.

Variable	Non Hospitalized N = 1,887	Hospitalized N = 1,608
Age – mean years ± SD	39.1 ± 11.9	54.1 ± 14.5
Sex - N (%)		
Female (%)	1253 (66.4)	668 (41.5)
GIA* – % mean ±SD		
European	54.4 ± 16.2	39.4 ± 20.7
African	15.3 ± 12.7	9.1 ± 11.6
Native American	30.3 ± 19.8	51.46 ± 26.5
Comorbidities - N (%)		
Vascular/endocrinological	488 (25.9)	873 (54.3)
Cardiac	60 (3.2)	150 (9.3)
Nervous	15 (0.8)	61 (3.8)
Digestive	14 (0.7)	33 (2.0)
Onco-hematological	21 (1.1)	48 (3.00)
Respiratory	76 (4.0)	118 (7.3)

988 *Global genetic inferred ancestry.

989

990 Table 2. Lead independent variants in the admixed AMR GWAS meta-analysis.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	EAF	EAF	Nearest
						cases	controls	gene

<i>rs13003835</i>	2:159407982	T	C	1.20 (1.12-1.27)	3.66E-08	0.563	0.429	<i>BAZ2B</i>
<i>rs35731912</i>	3:45848457	T	C	1.65 (1.47-1.85)	6.30E-17	0.087	0.056	<i>LZTFL1</i>
<i>rs2477820</i>	6:41535254	A	T	0.84 (0.79-0.89)	1.89E-08	0.453	0.517	<i>FOXP4-AS1</i>
<i>rs77599934</i>	11:82906875	G	A	2.27 (1.7-3.04)	2.26E-08	0.016	0.011	<i>DDIAS</i>

991 EA: effect allele; NEA: non-effect allele; EAF: effect allele frequency in the SCOURGE study.

992

993 Table 3. Novel variants in the SC-HGI_{ALL} and SC-HGI_{3POP} meta-analyses (with respect


994 to HGIv7). Independent signals after LD clumping.

<i>SNP rsID</i>	<i>chr:pos</i>	<i>EA</i>	<i>NEA</i>	<i>OR (95% CI)</i>	<i>P-value</i>	<i>Nearest gene</i>	<i>Analysis</i>
<i>rs76564172</i>	16:3892266	T	G	1.31 (1.19-1.44)	9.64E-09	<i>CREBBP</i>	SC-HGI _{3POP}
<i>rs66833742</i>	19:4063488	T	C	0.94 (0.92-0.96)	1.89E-08	<i>ZBTB7A</i>	SC-HGI _{3POP}
<i>rs66833742</i>	19:4063488	T	C	0.94 (0.92-0.96)	2.50E-08	<i>ZBTB7A</i>	SC-HGI _{ALL}
<i>rs2876034</i>	20:6492834	A	T	0.95 (0.93-0.97)	2.83E-08	<i>CASC20</i>	SC-HGI _{ALL}

995 EA: effect allele; NEA: non-effect allele.

996

997 **Figure 1. Flow chart of this study.**




998

999

1000

1001


1002 Figure 2. A) Manhattan plot for the admixed AMR GWAS meta-analysis. Probability
1003 thresholds at $p=5 \times 10^{-8}$ and $p=5 \times 10^{-5}$ are indicated by the horizontal lines. Genome-wide
1004 significant associations with COVID-19 hospitalizations were found in chromosome 2
1005 (within *BAZ2B*), chromosome 3 (within *LZTFL1*), chromosome 6 (within *FOXP4*), and
1006 chromosome 11 (within *DDIAS*). A Quantile-Quantile plot is shown in supplementary
1007 Figure 2. B) Regional association plots for rs1003835 at chromosome 2 and rs7759934
1008 at chromosome 11; C) Allele frequency distribution across The 1000 Genomes Project
1009 populations for the lead variants rs1003835 and rs7759934.



1010

1011

1012 Figure 3. Forest plot showing effect sizes and the corresponding confidence intervals for
1013 the sentinel variants identified in the AMR meta-analysis across populations. All beta
1014 values with their corresponding CIs were retrieved from the B2 population-specific
1015 meta-analysis from the HGI v7 release, except for AMR, for which the beta value and
1016 IC from the HGI_{AMR}-SCOURGE meta-analysis is represented.
1017




1018

1019

1020 Figure 4. (A) Polygenic risk stratified by PGS deciles comparing each risk group
1021 against the lowest risk group (OR-95%CI); (B) Distribution of the PGS scores in each

1022 of the severity scale classes (0-Asymptomatic, 1-Mild disease, 2-Moderate disease, 3-
1023 Severe disease, 4-Critical disease).



1024

1025


1026

1027 **Supplementary Material for: Novel risk loci for COVID-19 hospitalization among**
1028 **admixed American populations**

1029 Supplementary Tables are provided in a separate excel file

1030 **Supplementary figures**

1031 **Supplementary Figure 1. Global Genetic Inferred Ancestry (GIA) composition in**
1032 **the SCOURGE Latin-American cohort.** European (EUR), African (AFR) and Native
1033 American (AMR) GIA was derived with ADMIXTURE from a reference panel
1034 composed of Aymaran, Mayan, Nahuatl, and Quechuan individuals of Native-American
1035 genetic ancestry and randomly selected samples from the EUR and AFR 1KGP
1036 populations. The colours represent the different geographical sampling regions from
1037 which the admixed American individuals from SCOURGE were recruited.




1038

1039

1040 **Supplementary Figure 2. Quantile-Quantile plot for the AMR GWAS meta-**
1041 **analysis.** A lambda inflation factor of 1.015 was obtained.

1042



1043

1044

1045

1046

1047

1048

1049


1050

1051


1052

1053

1054 **Supplementary Figure 3. Regional association plots for the fine mapped loci in**
1055 **chromosomes 2 (upper panel) and 16 (lower panel).** Coloured in red, the variants
1056 allocated to the credible set at the 95% confidence according to the Bayesian fine
1057 mapping. In blue, the sentinel variant.



1058



1059

1060

1061 **Supplementary Figure 4. Sensitivity plots from COLOC with expression data from**
1062 **GTEx v8.** The range of p_{12} values (probability that a SNP is associated with both

1063 traits) for which the rule $H_4 > 0.7$ is supported is shown in green in the right plots for

1064 each analysis. Plots in the left represent the variants included in the risk region common

1065 to both traits along their individual association $-\log_{10}(p)$ for each trait, whereas


1066 the shading shows the posterior probability that the SNP is causal given H_4 is true. Trait

1067 1 corresponds to COVID-19 hospitalization, while trait 2 corresponds to gene

1068 expression in each analysis.


1069

LY75 in whole blood




1070

LY75 in lung




1071

BAZZ2B in whole blood



1072

LY75 in esophagus mucosa




1073

1074


1075 **Supplementary Figure 5. Sensitivity plots from COLOC with whole blood**
1076 **expression data from the GALA and SAGE II studies in AMR individuals.** *AFRhp5*
1077 corresponds to the expression dataset computed in individuals with high African
1078 ancestries; *AMRhp5* corresponds to the expression dataset computed individuals with
1079 high AMR ancestries; *pooled* corresponds to the dataset computed with the total of
1080 individuals from the study. In the right, the plots show in green the range of p_{12} values
1081 (probability that a SNP is associated with both traits) for which the rule $H_4 > 0.7$ is
1082 supported. Plots in the left represent the variants included in the risk region common to
1083 both traits along their individual association $-\log_{10}(p\text{-values})$ for each trait, whereas the
1084 shading shows the posterior probability that the SNP is causal given H_4 is true. Trait 1
1085 corresponds to COVID-19 hospitalization, while trait 2 corresponds to gene expression.

CD302 In whole blood AFRhp5




1086

BAZ2B in whole blood AFRhp5




1087

WDSUB1 in whole blood AFRhp5




1088

LY75 In whole blood AFRhp5




1089

LY75 in whole blood AMRhp5




1090

LY75 in whole blood pooled



1091

CD302 in whole blood pooled




1092

1093

1094

1095 **Supplementary Figure 6. Gene-tissue pairs for which either rs1003835 or**
1096 **rs60606421 are significant eQTLs at FDR<0.05 (data retrieved from**
1097 **<https://gtexportal.org/home/snp/>). rs1003835 (chromosome 2) maps to *BAZ2B*, *LY75*,**
1098 **and *PLA2R* genes. As for the lead variant of chromosome 11, rs77599934, since it was**
1099 **not an eQTL, we used an LD proxy variant (rs60606421). *DDIAS* and *PRCP* genes map**
1100 **closely to this variant. NES and p-values correspond to the normalized effect size (and**
1101 **direction) of eQTL-gene associations and the p-value for the tissue, respectively.**

1102



1103

1104

1105 **Scourge Cohort Group**

1106 Full list of cohort members and affiliations

1107 Javier Abellan^{1,2}; René Acosta-Isaac³; Jose María Aguado^{4,5,6,7}; Carlos Aguilar⁸; Sergio
 1108 Aguilera-Albesa^{9,10}; Abdolah Ahmadi Sabbagh¹¹; Jorge Alba¹²; Sergiu Albu^{13,14,15};
 1109 Karla A.M. Alcalá-Gallardo¹⁶; Julia Alcoba-Florez¹⁷; Sergio Alcolea Batres¹⁸; Holmes
 1110 Rafael Algarin-Lara^{19,20}; Virginia Almadana²¹; Julia Almeida^{22,23,24,25}; Berta
 1111 Almoguera^{26,27}; María R. Alonso²⁸; Nuria Alvarez²⁸; Rodolfo Alvarez-Sala Walther¹⁸;
 1112 Mónica T. Andrade^{29,30}; Álvaro Andreu-Bernabeu^{31,6}; Maria Rosa Antonijoan³²; Eunat

1113 Arana-Arri^{33,34}; Carlos Aranda^{35,36}; Celso Arango^{31,37,6}; Carolina Araque^{38,39}; Nathalia
1114 K. Araujo⁴⁰; Izabel M.T. Araujo⁴¹; Ana C. Arcanjo^{42,43,44}; Ana Arnaiz^{45,46,47}; Francisco
1115 Arnalich Fernández⁴⁸; María J. Arranz⁴⁹; José Ramon Arribas Lopez⁴⁸; Maria-Jesus
1116 Artiga⁵⁰; Yubelly Avello-Malaver⁵¹; Carmen Ayuso^{26,27}; Ana Margarita Baldión⁵¹;
1117 Belén Ballina Martín¹¹; Raúl C. Baptista-Rosas^{52,53,54}; Andrea Barranco-Díaz²⁰; María
1118 Barreda- Sánchez^{55,56}; Viviana Barrera-Penagos⁵¹; Moncef Belhassen-García^{57,58};
1119 Enrique Bernal⁵⁵; David Bernal-Bello⁵⁹; Joao F. Bezerra⁶⁰; Marcos A.C. Bezerra⁶¹;
1120 Natalia Blanca-López⁶²; Rafael Blancas⁶³; Lucía Boix-Palop⁶⁴; Alberto Borobia⁶⁵; Elsa
1121 Bravo⁶⁶; María Brion^{67,68}; Óscar Brochado-Kith^{69,7}; Ramón Brugada^{70,71,68,72}; Matilde
1122 Bustos⁷³; Alfonso Cabello⁷⁴; Juan J. Caceres-Agra⁷⁵; Esther Calbo⁷⁶; Enrique J.
1123 Calderón^{77,78,79}; Shirley Camacho⁸⁰; Cristina Carbonell^{81,58}; Servando Cardona-
1124 Huerta⁸²; Antonio Augusto F. Carioca⁸³; Maria Sanchez Carpintero^{35,36}; Carlos Carpio
1125 Segura¹⁸; Thássia M.T. Carratto⁸⁴; José Antonio Carrillo-Avila⁸⁵; Maria C.C.
1126 Carvalho⁸⁶; Carlos Casasnovas^{87,88,27}; Luis Castano^{33,34,27,89,90}; Carlos F. Castaño^{35,36};
1127 Jose E. Castelao⁹¹; Aranzazu Castellano Candalija⁹²; María A. Castillo⁸⁰; Yolanda
1128 Cañadas³⁶; Francisco C. Ceballos²⁷; Jessica G. Chaux³⁹; Walter G. Chaves-
1129 Santiago^{93,39}; Sylena Chiquillo-Gómez^{19,20}; Marco A. Cid-Lopez¹⁶; Oscar Cienfuegos-
1130 Jimenez⁸²; Rosa Conde-Vicente⁹⁴; M. Lourdes Cordero-Lorenzana⁹⁵; Dolores
1131 Corella^{96,97}; Almudena Corrales^{98,99}; Jose L. Cortes-Sanchez^{82,100}; Marta Corton^{26,27};
1132 Tatiana X. Costa¹⁰¹; Raquel Cruz^{27,102}; Marina S. Cruz⁴⁰; Luisa Cuesta¹⁰³; Gabriela C.R.
1133 Cunha¹⁰⁴; David Dalmau^{105,76}; Raquel C.S. Dantas-Komatsu⁴⁰; M. Teresa Darnaude¹⁰⁶;
1134 Alba De Martino-Rodríguez^{107,108}; Juan De la Cruz Troca^{109,110,78}; Juan Delgado-
1135 Cuesta¹¹¹; Aranzazu Diaz de Bustamante¹⁰⁶; Covadonga M. Diaz-Caneja^{31,37,6}; Beatriz
1136 Dietl⁷⁶; Silvia Diz-de Almeida^{27,102}; Elena Domínguez-Garrido¹¹²; Alice M. Duarte⁴¹;
1137 Anderson Díaz-Pérez²⁰; Jose Echave-Sustaeta¹¹³; Rocío Eiros¹¹⁴; César O. Enciso-
1138 Olivera^{38,39}; Gabriela Escudero¹¹⁵; Pedro Pablo España¹¹⁶; Gladys Mercedes Estigarribia
1139 Sanabria¹¹⁷; María Carmen Fariñas^{45,46,47}; Marianne R. Fernandes^{118,119}; Lidia
1140 Fernandez-Caballero^{26,27}; María J. Fernandez-Nestosa¹²⁰; Ramón Fernández^{45,121}; Silvia
1141 Fernández Ferrero¹¹; Yolanda Fernández Martínez¹¹; Ana Fernández-Cruz¹²²; Uxía
1142 Fernández-Robelo¹²³; Amanda Fernández-Rodríguez^{69,7}; Marta Fernández-
1143 Sampetro^{45,47,46}; Ruth Fernández-Sánchez^{26,27}; Tania Fernández-Villa^{124,78}; Carmen
1144 Fernández Capitán⁹²; Patricia Flores-Pérez¹²⁵; Vicente Friaiza^{78,79}; Lácides Fuenmayor-
1145 Hernández²⁰; Marta Fuertes Núñez¹¹; Victoria Fumadó¹²⁶; Ignacio Gadea¹²⁷; Lidia
1146 Gagliardi^{35,36}; Manuela Gago-Domínguez^{128,129}; Natalia Gallego¹³⁰; Cristina Galoppo¹³¹;
1147 Carlos Garcia-Cerrada^{1,2,132}; Josefina Garcia-García⁵⁵; Inés García^{26,27}; Mercedes
1148 García^{35,36}; Leticia García^{35,36}; María Carmen García Torrejón^{133,2}; Irene García-
1149 García⁶⁵; Carmen García-Ibarbia^{45,47,46}; Andrés C. García-Montero¹³⁴; Ana García-
1150 Soidán¹³⁵; Elisa García-Vázquez⁵⁵; Aitor García-de-Vicuña^{33,136}; Emiliano Garza-
1151 Frias⁸²; Jesus Gaytán-Martínez¹³⁷; Angela Gentile¹³¹; Belén Gil-Fournier¹³⁸; Fernan
1152 Gonzalez Bernaldo de Quirós¹³⁹; Manuel Gonzalez-Sagrado⁹⁴; Hugo Gonzalo Benito¹⁴⁰;
1153 Beatriz González Álvarez^{107,108}; Anna González-Neira²⁸; Javier González-Peñas^{31,6,37};
1154 Oscar Gorgojo-Galindo¹⁴¹; Florencia Guaragna¹³¹; Genilson P. Guegel¹⁴²; Beatriz
1155 Guillen-Guio⁹⁸; Encarna Guillen-Navarro^{55,143,144,27}; Pablo Guisado-Vasco¹¹³; Luz D.
1156 Gutierrez-Castañeda^{145,39}; Juan F. Gutiérrez-Bautista¹⁴⁶; Luis Gómez Carrera¹⁸; María

1157 Gómez García¹²⁸; Ángela Gómez Sacristán¹⁴⁷; Javier Gómez-Arrue^{107,108}; Mario
1158 Gómez-Duque^{93,39}; Miguel Górgolas⁷⁴; Sarah Heili-Frades¹⁴⁸; Estefania Hernandez¹⁴⁹;
1159 Luis D. Hernandez-Ortega^{150,151}; Cristina Hernández Moro¹¹; Guillermo Hernández-
1160 Pérez⁸¹; Rebeca Hernández-Vaquero¹⁵²; Belen Herraez²⁸; M. Teresa Herranz⁵⁵; María
1161 Herrera^{35,36}; María José Herrero^{153,154}; Antonio Herrero-Gonzalez¹⁵⁵; Juan P.
1162 Horcajada^{156,157,14,158,7}; Natale Imaz-Ayo³³; Mainer Intxausti-Urrutibeaskoa¹⁵⁹; Rafael H.
1163 Jacomo¹⁶⁰; Rubén Jara⁵⁵; Perez Maria Jazmin¹³¹; María A. Jimenez-Sousa^{69,7}; Ángel
1164 Jiménez^{35,36}; Pilar Jiménez¹⁴⁶; Ignacio Jiménez-Alfaro¹⁶¹; Iolanda Jordan^{162,163,78}; Rocío
1165 Laguna-Goya^{164,165}; Daniel Laorden¹⁸; María Lasa-Lazaro^{164,165}; María Claudia
1166 Lattig^{80,166}; Ailen Lauriente¹³¹; Anabel Liger Borja¹⁶⁷; Lucía Llanos¹⁶⁹; Esther Lopez-
1167 Garcia^{109,110,78,170}; Rosario Lopez-Rodriguez^{26,27}; Leonardo Lorente¹⁷¹; José E.
1168 Lozano¹⁷²; María Lozano-Espinosa¹⁶⁷; Andre D. Luchessi¹⁷³; Eduardo López
1169 Granados^{174,175,27}; Amparo López-Bernús^{81,58}; Miguel A. López-Ruz^{176,177,178}; Aluísio X.
1170 Magalhães-Brasil¹⁷⁹; Ignacio Mahillo^{180,181,99}; Esther Mancebo^{164,165}; Carmen Mar¹¹⁶;
1171 Cristina Marcelo Calvo⁹²; Miguel Marcos^{81,58}; Alba Marcos-Delgado¹²⁴; Pablo Mariscal
1172 Aguilar¹⁸; Marta Martin-Fernandez¹⁸²; Laura Martin-Pedraza⁶²; Amalia Martinez¹⁸³;
1173 Iciar Martinez-Lopez^{184,185}; Oscar Martinez-Nieto^{51,166}; Pedro Martinez-Paz¹⁴⁰; Angel
1174 Martinez-Perez¹⁸⁶; Michel F. Martinez-Resendez⁸²; María M. Martín¹⁸⁷; María Dolores
1175 Martín¹⁸⁸; Vicente Martín^{124,78}; Caridad Martín-López¹⁶⁷; José-Ángel Martín-
1176 Oterino^{81,58}; María Martín-Vicente⁶⁹; Ricardo Martínez¹⁴⁹; Juan José Martínez^{88,27};
1177 Silvia Martínez^{45,47}; Violeta Martínez Robles¹¹; Eleno Martínez-Aquino¹⁸⁹; Óscar
1178 Martínez-González¹⁹⁰; Andrea Martínez-Ramas^{26,27}; Laura Marzal^{26,27}; Alicia Marín
1179 Candon⁶⁵; Jose Antonio Mata-Marin,¹³⁷ Juliana F. Mazzeu^{179,191,192}; Jeane F.P.
1180 Medeiros⁴⁰; Francisco J. Medrano^{77,78,79}; Xose M. Meijome^{193,194}; Natalia Mejuto-
1181 Montero¹⁹⁵; Celso T. Mendes-Junior^{84,196,197}; Humberto Mendoza Charris^{66,20}; Eleuterio
1182 Merayo Macías¹⁹⁸; Fátima Mercadillo¹⁹⁹; Arie R. Mercado-Sesma^{150,151}; Pablo
1183 Minguez^{26,27}; Antonio J J. Molina^{124,78}; Elena Molina-Roldán²⁰⁰; Juan José Montoya¹⁴⁹;
1184 Patricia Moreira-Escriche²⁰¹; Xenia Morelos-Arnedo^{66,20}; Victor Moreno Cuerda^{1,2};
1185 Alberto Moreno Fernández⁹²; Antonio Moreno-Docón⁵⁵; Junior Moreno-Escalante²⁰;
1186 Rubén Morilla^{79,202}; Patricia Muñoz García^{203,99,6}; Ana Méndez-Echevarria²⁰⁴; Pablo
1187 Neira¹³¹; Julian Nevado^{27,131,205}; Israel Nieto-Gañán¹³⁵; Joana F.R. Nunes⁴²; Rocio
1188 Nuñez- Torres²⁸; Antònia Obrador-Hevia^{206,207}; J. Gonzalo Ocejo-Vinyals^{45,47}; Virginia
1189 Olivar¹³¹; Silviene F. Oliveira^{179,208,208,210,211}; Lorena Ondo^{26,27}; Alberto Orfao^{22,23,24,25};
1190 Luis Ortega²¹²; Eva Ortega-Paino⁵⁰; Fernando Ortiz-Flores^{45,47}; Rocio Ortiz-Lopez^{213,82};
1191 José A. Oteo^{12,214}; Harry Pachajoa^{215,216}; Manuel Pacheco¹⁴⁹; Fredy Javier Pacheco-
1192 Miranda²⁰; Irene Padilla Conejo¹¹; Sonia Panadero-Fajardo⁸⁵; Mara Parellada^{31,37,6};
1193 Roberto Pariente-Rodríguez¹³¹; Estela Paz-Artal^{164,165,217}; Germán Peces-Barba^{218,99};
1194 Miguel S. Pedromingo Kus²¹⁹; Celia Perales¹²⁷; Patricia Perez²²⁰; Gustavo Perez-de-
1195 Nanclares^{33,221}; Teresa Perucho²²²; Aline Pic-Taylor^{42,208,209,211}; Lisbeth A. Pichardo¹¹;
1196 Mel-lina Pinsach-Abuin^{70,68}; Luz Adriana Pinzón^{93,39}; Guillermo Pita³⁰; Francesc Pla-
1197 Junca^{223,27}; Laura Planas-Serra^{88,27}; Ericka N. Pompa-Mera^{224,137}; Gloria L. Porras-
1198 Hurtado¹⁴⁹; Aurora Pujol^{88,27,225}; César Pérez²²⁶; Felipe Pérez-García^{227,228}; Patricia
1199 Pérez-Matute²¹⁴; Alexandra Pérez-Serra^{70,68}; M. Elena Pérez-Tomás⁵⁵; María Eugenia
1200 Quevedo Chávez^{19,20}; Maria Angeles Quijada^{30,229}; Inés Quintela¹²⁸; Diana Ramirez-

1201 Montaña²³⁰; Soraya Ramiro León¹³¹; Pedro Rascado Sedes²³¹; Delia Recalde^{107,108};
1202 Emma Recio-Fernández²¹⁴; Salvador Resino^{69,7}; Adriana P. Ribeiro^{29,30,232}; Carlos S.
1203 Rivadeneira-Chamorro³⁹; Diana Roa-Agudelo⁵¹; Montserrat Robelo Pardo²³¹; Marilyn
1204 Johanna Rodriguez³⁹; German Ezequiel Rodriguez Novoa¹³¹; Fernando Rodriguez-
1205 Artalejo^{109,110,78,170}; Carlos Rodriguez-Gallego^{233,234}; José A. Rodriguez-Garcia¹¹; María
1206 A. Rodriguez-Hernandez⁷³; Antonio Rodriguez-Nicolas¹⁴⁶; Agustí Rodriguez-
1207 Palmero^{235,88}; Paula A. Rodriguez-Urrego⁵¹; Belén Rodríguez Maya¹; Marena
1208 Rodríguez-Ferrer²⁰; Emilio Rodríguez-Ruiz^{231,129}; Federico Rojo^{236,25}; Andrea Romero-
1209 Coronado²⁰; Filomeno Rondón García¹¹; Lidia S. Rosa²³⁶; Antonio Rosales-Castillo²³⁷;
1210 Cladelis Rubio^{238,239}; María Rubio Olivera^{35,36}; Montserrat Ruiz^{88,27}; Francisco Ruiz-
1211 Cabello^{146,177,240}; Eva Ruiz-Casares²²²; Juan J. Ruiz-Cubillan^{45,47}; Javier Ruiz-
1212 Hornillos^{241,36,242}; Pablo Ryan^{243,244,245,7}; Hector D. Salamanca^{38,39}; Lorena Salazar-
1213 García⁸⁰; Giorgina Gabriela Salgueiro Origlia⁹²; Cristina Sancho-Sainz¹⁵⁹; Jorge Luis
1214 Sandoval-Ramírez,¹³⁷ Anna Sangil⁶⁴; Arnoldo Santos²²⁶; Ney P.C. Santos¹¹⁸; Amanda
1215 C.M. Saúde^{30,246} Agatha Schlüter^{88,27}; Sonia Segovia^{223,247,248}; Alex Serra-Llovich²⁴⁹;
1216 Fernando Sevil Puras⁸; Marta Sevilla Porras^{27,130}; Miguel A. Siculo^{250,251}; Vivian N.
1217 Silbiger¹⁷³; Nayara S. Silva²⁵²; Fabiola T.C. Silva⁴⁰; Cristina Silván Fuentes²⁷; Jordi
1218 Solé-Violán^{253,99,254}; José Manuel Soria¹⁸⁶; Jose V. Sorli^{96,97}; Renata R. Sousa¹⁷⁹; Juan
1219 Carlos Souto³; Karla S.C. Souza⁸⁶; Vanessa S. Souza¹⁰⁴; John J. Sprockel^{93,39}; David A.
1220 Suarez-Zamora⁵¹; José Javier Suárez-Rama¹²⁸; Pedro-Luis Sánchez^{114,58}; Antonio J.
1221 Sánchez López²⁵⁵; María Concepción Sánchez Prados¹⁸; Javier Sánchez Real¹¹; Jorge
1222 Sánchez Redondo^{1,256}; Clara Sánchez-Pablo¹¹⁴; Olga Sánchez-Pernaute²⁵⁷; Xiana
1223 Taboada-Fraga¹⁹⁵; Eduardo Tamayo^{258,140,7}; Alvaro Tamayo-Velasco²⁵⁹; Juan Carlos
1224 Taracido-Fernandez¹⁵⁵; Nathali A.C. Tavares²⁶⁰; Carlos Tellería^{107,108}; Jair Antonio
1225 Tenorio Castaño^{27,130,205}; Alejandro Teper¹³¹; Ronald P. Torres Gutiérrez²²¹; Juan
1226 Torres-Macho²⁶¹; Lilian Torres-Tobar³⁹; Jesús Troya²⁴³; Miguel Urioste¹⁹⁹; Juan
1227 Valencia-Ramos²⁶²; Agustín Valido^{21,263}; Juan Pablo Vargas Gallo^{264,265}; Belén
1228 Varón²⁶⁶; Romero H.T. Vasconcelos²⁶⁰; Tomas Vega²⁶⁷; Santiago Velasco-Quirce²⁶⁸;
1229 Julia Vidán Estévez¹¹; Miriam Vieitez-Santiago^{45,47}; Carlos Vilches²⁶⁹; Lavinia
1230 Villalobos¹¹; Felipe Villar²¹⁸; Judit Villar-García^{270,271,272}; Cristina Villaverde^{26,27}; Pablo
1231 Villoslada-Blanco²¹⁴; Ana Virseda-Berdices⁶⁹; Valentina Vélez-Santamaría^{87,88};
1232 Virginia Víctor^{35,36}; Zuleima Yáñez²⁰; Antonio Zapatero-Gaviria²⁷³; Ruth Zarate²⁷⁴;
1233 Sandra Zazo²³⁶; Gabriela V. da Silva⁴¹; Raimundo de Andrés²⁷⁵; Jéssica N.G. de
1234 Araújo²⁵²; Carmen de Juan²⁰¹; Julianna Lys de Sousa Alves Neri²⁷⁶; Carmen de la
1235 Horra⁷⁹; Ana B. de la Hoz³³; Victor del Campo-Pérez²⁷⁷; Manoella do Monte
1236 Alves^{278,279}; Katusse A. dos Santos⁸⁶; Yady Álvarez-Benítez^{19,20}; Felipe Álvarez-
1237 Navia^{81,58}; María Íñiguez²¹⁴; Miguel López de Heredia²⁷; Ingrid Mendes²⁷; Rocío
1238 Moreno²⁷; Esther Sande^{27,129,102}; Carlos Flores^{280,98,99,234}; José A. Riancho^{45,46,47,27};
1239 Augusto Rojas-Martinez⁸²; Pablo Lapunzina^{27,130,205}; Angel Carracedo^{27,129,102,128}

1240 Scourge Cohort Group's filiations

1241 ¹, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain

1242 ², Universidad Francisco de Vitoria, Madrid, Spain

- 1243 ³, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
1244 Barcelona, Spain
- 1245 ⁴, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
1246 Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- 1247 ⁵, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
1248 Salud Carlos III, Madrid, Spain
- 1249 ⁶, School of Medicine, Universidad Complutense, Madrid, Spain
- 1250 ⁷, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC),
1251 Instituto de Salud Carlos III, Madrid, Spain
- 1252 ⁸, Hospital General Santa Bárbara de Soria, Soria, Spain
- 1253 ⁹, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
1254 Pamplona, Spain
- 1255 ¹⁰, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 1256 ¹¹, Complejo Asistencial Universitario de León, León, Spain
- 1257 ¹², Hospital Universitario San Pedro, Infectious Diseases Department, Logroño, Spain
- 1258 ¹³, Fundació Institut Guttmann, Institut Universitari de Neurorehabilitació adscrit a la UAB,
1259 Hospital de Neurorehabilitació, Barcelona, Spain
- 1260 ¹⁴, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- 1261 ¹⁵, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona,
1262 Spain
- 1263 ¹⁶, Hospital General de Occidente, Guadalajara, Mexico
- 1264 ¹⁷, Microbiology Unit, Hospital Universitario N. S. de Candelaria, Santa Cruz de Tenerife,
1265 Spain
- 1266 ¹⁸, Hospital Universitario La Paz-IDIPAZ, Servicio de Neumología, Madrid, Spain
- 1267 ¹⁹, Camino Universitario Adelita de Char, Mired IPS, Barranquilla, Colombia
- 1268 ²⁰, Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
- 1269 ²¹, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 1270 ²², Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
- 1271 ²³, Centro de Investigación del Cáncer (IBMCC) Universidad de Salamanca - CSIC, Salamanca,
1272 Spain
- 1273 ²⁴, Biomedical Research Institute of Salamanca (IBSAL) Salamanca, Spain
- 1274 ²⁵, Centre for Biomedical Network Research on Cancer (CIBERONC), Instituto de Salud Carlos
1275 III, Madrid, Spain
- 1276 ²⁶, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
1277 Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1278 ²⁷, Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud
1279 Carlos III, Madrid, Spain
- 1280 ²⁸, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- 1281 ²⁹, Hospital das Forças Armadas, Brazil

- 1282 ³⁰, Exército Brasileiro, Brazil
- 1283 ³¹, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
1284 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 1285 ³², Clinical Pharmacology Service, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
1286 Barcelona, Spain
- 1287 ³³, Biocruces Bizkai HRI, Barakaldo, Bizkaia, Spain
- 1288 ³⁴, Cruces University Hospital, Osakidetza, Barakaldo, Bizkaia, Spain
- 1289 ³⁵, Hospital Infanta Elena, Valdemoro, Madrid, Spain
- 1290 ³⁶, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
1291 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1292 ³⁷, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
1293 Carlos III, Madrid, Spain
- 1294 ³⁸, Fundación Hospital Infantil Universitario de San José, Bogotá, Colombia
- 1295 ³⁹, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
- 1296 ⁴⁰, Universidade Federal do Rio Grande do Norte, Programa de Pós-graduação em Ciências da
1297 Saúde, Natal, Brazil
- 1298 ⁴¹, Universidade Federal do Rio Grande do Norte, Departamento de Medicina Clínica, Natal,
1299 Brazil
- 1300 ⁴², Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
1301 Brasília, Brasilia, Brazil
- 1302 ⁴³, Colégio Marista de Brasília, Brazil
- 1303 ⁴⁴, Associação Brasileira de Educação e Cultura, Brazil
- 1304 ⁴⁵, IDIVAL, Santander, Spain
- 1305 ⁴⁶, Universidad de Cantabria, Santander, Spain
- 1306 ⁴⁷, Hospital U M Valdecilla, Santander, Spain
- 1307 ⁴⁸, Hospital Universitario La Paz-IDIPAZ, Servicio de Medicina Interna, Madrid, Spain
- 1308 ⁴⁹, Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 1309 ⁵⁰, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 1310 ⁵¹, Fundación Santa Fe de Bogota, Departamento Patología y Laboratorios, Bogotá, Colombia
- 1311 ⁵², Hospital General de Occidente, Zapopan, Jalisco, Mexico
- 1312 ⁵³, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jalisco, Mexico
- 1313 ⁵⁴, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá,
1314 Jalisco, Mexico
- 1315 ⁵⁵, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- 1316 ⁵⁶, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- 1317 ⁵⁷, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
1318 Enfermedades Infecciosas, Salamanca, Spain
- 1319 ⁵⁸, Universidad de Salamanca, Salamanca, Spain

- 1320 ⁵⁹, Hospital Universitario de Fuenlabrada, Department of Internal Medicine, Madrid, Spain
- 1321 ⁶⁰, Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Pará, Brazil
- 1322 ⁶¹, Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 1323 ⁶², Hospital Universitario Infanta Leonor, Servicio de Alergia, Madrid, Spain
- 1324 ⁶³, Hospital Universitario del Tajo, Servicio de Medicina Intensiva, Aranjuez, Spain
- 1325 ⁶⁴, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- 1326 ⁶⁵, Hospital Universitario La Paz-IDIPAZ, Servicio de Farmacología, Madrid, Spain
- 1327 ⁶⁶, Alcaldía de Barranquilla, Secretaría de Salud, Barranquilla, Colombia
- 1328 ⁶⁷, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
1329 Compostela, Spain
- 1330 ⁶⁸, Centre for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Instituto
1331 de Salud Carlos III, Madrid, Spain
- 1332 ⁶⁹, Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
1333 de Salud Carlos III (ISCIII), Madrid, Spain
- 1334 ⁷⁰, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
1335 Spain
- 1336 ⁷¹, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 1337 ⁷², Hospital Josep Trueta, Cardiology Service, Girona, Spain
- 1338 ⁷³, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
1339 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- 1340 ⁷⁴, Division of Infectious Diseases, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
1341 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1342 ⁷⁵, Intensive Care Unit, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran
1343 Canaria, Spain
- 1344 ⁷⁶, Hospital Universitario Mutua Terrassa, Terrassa, Spain
- 1345 ⁷⁷, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
1346 Seville, Spain
- 1347 ⁷⁸, Centre for Biomedical Network Research on Epidemiology and Public Health (CIBERESP),
1348 Instituto de Salud Carlos III, Madrid, Spain
- 1349 ⁷⁹, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
1350 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- 1351 ⁸⁰, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia
- 1352 ⁸¹, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
1353 Spain
- 1354 ⁸², Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud and Hospital San
1355 Jose TecSalud, Monterrey, Mexico
- 1356 ⁸³, University of Fortaleza (UNIFOR), Department of Nutrition. Fortaleza, Brazil
- 1357 ⁸⁴, Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto,
1358 Universidade de São Paulo, Brazil

- 1359 ⁸⁵, Andalusian Public Health System Biobank, Granada, Spain
- 1360 ⁸⁶, Universidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Ciências
1361 Farmacêuticas, Natal, Brazil
- 1362 ⁸⁷, Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge,
1363 L'Hospitalet de Llobregat (Barcelona), Spain
- 1364 ⁸⁸, Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
1365 L'Hospitalet de Llobregat, Spain
- 1366 ⁸⁹, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
1367 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 1368 ⁹⁰, University of Pais Vasco, UPV/EHU, Bizkaia, Spain
- 1369 ⁹¹, Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de
1370 Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 1371 ⁹², Hospital Universitario La Paz, Hospital Carlos III, Madrid, Spain
- 1372 ⁹³, Hospital de San José, Sociedad de Cirugía de Bogota, Bogotá, Colombia
- 1373 ⁹⁴, Hospital Universitario Río Hortega, Valladolid, Spain
- 1374 ⁹⁵, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
1375 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 1376 ⁹⁶, Valencia University, Preventive Medicine Department, Valencia, Spain
- 1377 ⁹⁷, Centre for Biomedical Network Research on Physiopatology of Obesity and Nutrition
1378 (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- 1379 ⁹⁸, Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain
- 1380 ⁹⁹, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de
1381 Salud Carlos III, Madrid, Spain
- 1382 ¹⁰⁰, Otto von Guericke University, Department of Microgravity and Translational Regenerative
1383 Medicine, Magdeburg, Germany
- 1384 ¹⁰¹, Maternidade Escola Janário Cicco, Natal, Brazil
- 1385 ¹⁰², Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas
1386 (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 1387 ¹⁰³, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón
1388 (IiSGM), Madrid, Spain
- 1389 ¹⁰⁴, Programa de Pós Graduação em Ciências da Saúde, Faculdade de Medicina, Universidade
1390 de Brasília, Brasilia, Brazil
- 1391 ¹⁰⁵, Fundació Docència I Recerca Mutua Terrassa, Terrassa, Spain
- 1392 ¹⁰⁶, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain
- 1393 ¹⁰⁷, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 1394 ¹⁰⁸, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- 1395 ¹⁰⁹, Department of Preventive Medicine and Public Health, School of Medicine, Universidad
1396 Autónoma de Madrid, Madrid, Spain
- 1397 ¹¹⁰, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain

- 1398 ¹¹¹, Hospital Universitario Virgen del Rocío, Servicio de Medicina Interna, Seville, Spain
- 1399 ¹¹², Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- 1400 ¹¹³, Hospital Universitario Quironsalud Madrid, Madrid, Spain
- 1401 ¹¹⁴, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 1402 ¹¹⁵, Hospital Universitario Puerta de Hierro, Servicio de Medicina Interna, Majadahonda, Spain
- 1403 ¹¹⁶, Biocruces Bizkaia Health Research Institute, Galdakao University Hospital, Osakidetza,
1404 Bizkaia, Spain
- 1405 ¹¹⁷, Instituto Regional de Investigación en Salud-Universidad Nacional de Caaguazú, Caaguazú,
1406 Paraguay
- 1407 ¹¹⁸, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil
- 1408 ¹¹⁹, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 1409 ¹²⁰, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
- 1410 ¹²¹, Fundación Asilo San Jose, Santander, Spain
- 1411 ¹²², Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario
1412 Puerta de Hierro, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana,
1413 Madrid, Spain
- 1414 ¹²³, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
1415 Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 1416 ¹²⁴, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) - Instituto de
1417 Biomedicina (IBIOMED), Universidad de León, León, Spain
- 1418 ¹²⁵, Hospital Universitario Niño Jesús, Pediatrics Department, Madrid, Spain
- 1419 ¹²⁶, Unitat de Malalties Infeccioses i Importades, Servei de Pediatria, Infectious and Imported
1420 Diseases, Pediatric Unit, Hospital Universitari Sant Joan de Deú, Barcelona, Spain
- 1421 ¹²⁷, Microbiology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
1422 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1423 ¹²⁸, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
1424 Santiago de Compostela, Spain
- 1425 ¹²⁹, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
- 1426 ¹³⁰, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-
1427 IDIPAZ, Madrid, Spain
- 1428 ¹³¹, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
- 1429 ¹³², Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud
1430 Carlos III, Madrid, Spain Universidad Francisco de Vitoria, Madrid, Spain
- 1431 ¹³³, Hospital Infanta Elena, Servicio de Medicina Intensiva, Valdemoro, Madrid, Spain
- 1432 ¹³⁴, University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca,
1433 Spain
- 1434 ¹³⁵, Department of Immunology, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 1435 ¹³⁶, Osakidetza, Cruces University Hospital, Bizkaia, Spain

- 1436 ¹³⁷, Instituto Mexicano del Seguro Social, IMSS. Centro Médico Nacional La Raza. Hospital de
1437 Infectología. Mexico City, Mexico.
- 1438 ¹³⁸, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 1439 ¹³⁹, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- 1440 ¹⁴⁰, Hospital Clinico Universitario de Valladolid, Unidad de Apoyo a la Investigación,
1441 Valladolid, Spain
- 1442 ¹⁴¹, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain
- 1443 ¹⁴², Secretaria Municipal de Saude de Apodi, Natal, Brazil
- 1444 ¹⁴³, Sección Genética Médica - Servicio de Pediatría, Hospital Clínico Universitario Virgen de la
1445 Arrixaca, Servicio Murciano de Salud, Murcia, Spain
- 1446 ¹⁴⁴, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
1447 Universidad de Murcia (UMU), Murcia, Spain
- 1448 ¹⁴⁵, Hospital Universitario Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia
- 1449 ¹⁴⁶, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
1450 Granada, Spain
- 1451 ¹⁴⁷, Pneumology Department, Hospital General Universitario Gregorio Marañón (iiSGM),
1452 Madrid, Spain
- 1453 ¹⁴⁸, Intermediate Respiratory Care Unit, Department of Pneumology, Instituto de Investigación
1454 Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-
1455 FJD, UAM), Madrid, Spain
- 1456 ¹⁴⁸, Clinica Comfamiliar Risaralda, Pereira, Colombia
- 1457 ¹⁵⁰, Centro Universitario de Tonalá, Universidad de Guadalajara, Guadalajara, Mexico
- 1458 ¹⁵¹, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara,
1459 Guadalajara, Mexico
- 1460 ¹⁵², Unidad de Cuidados, Intensivos Hospital Clínico Universitario de Santiago (CHUS),
1461 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
- 1462 ¹⁵³, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 1463 ¹⁵⁴, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 1464 ¹⁵⁵, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
1465 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1466 ¹⁵⁶, Hospital del Mar, Infectious Diseases Service, Barcelona, Spain
- 1467 ¹⁵⁷, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
- 1468 ¹⁵⁸, CEXS-Universitat Pompeu Fabra, Spanish Network for Research in Infectious Diseases
1469 (REIPI), Barcelona, Spain
- 1470 ¹⁵⁹, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Osakidetza,
1471 Bizkaia, Spain
- 1472 ¹⁶⁰, Sabin Medicina Diagnóstica, Brazil
- 1473 ¹⁶¹, Ophthalmology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
1474 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1475 ¹⁶², Hospital Sant Joan de Deu, Pediatric Critical Care Unit, Barcelona, Spain

- 1476 ¹⁶³, Paediatric Intensive Care Unit, Agrupación Hospitalaria Clínic-Sant Joan de Déu,
1477 Esplugues de Llobregat, Barcelona, Spain
- 1478 ¹⁶⁴, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain
- 1479 ¹⁶⁵, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
1480 Immunology and Immunodeficiencies Group, Madrid, Spain
- 1481 ¹⁶⁶, SIGEN Alianza Universidad de los Andes - Fundación Santa Fe de Bogotá, Bogotá,
1482 Colombia
- 1483 ¹⁶⁷, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain
- 1484 ¹⁶⁸, Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Brasília, Brazil
- 1485 ¹⁶⁹, Clinical Trials Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University
1486 Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1487 ¹⁷⁰, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- 1488 ¹⁷¹, Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Spain
- 1489 ¹⁷², Dirección General de Salud Pública, Consejería de Sanidad, Junta de Castilla y León,
1490 Valladolid, Spain
- 1491 ¹⁷³, Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e
1492 Toxicologicas, Natal, Brazil
- 1493 ¹⁷⁴, Hospital Universitario La Paz-IDIPAZ, Servicio de Inmunología, Madrid, Spain
- 1494 ¹⁷⁵, La Paz Institute for Health Research (IdiPAZ), Lymphocyte Pathophysiology in
1495 Immunodeficiencies Group, Madrid, Spain
- 1496 ¹⁷⁶, Hospital Universitario Virgen de las Nieves, Servicio de Enfermedades Infecciosas,
1497 Granada, Spain
- 1498 ¹⁷⁷, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain
- 1499 ¹⁷⁸, Universidad de Granada, Departamento de Medicina, Granada, Spain
- 1500 ¹⁷⁹, Faculdade de Medicina, Universidade de Brasília, Brasilia, Brazil
- 1501 ¹⁸⁰, Fundación Jiménez Díaz, Epidemiology, Madrid, Spain
- 1502 ¹⁸¹, Universidad Autónoma de Madrid, Department of Medicine, Madrid, Spain
- 1503 ¹⁸², Universidad de Valladolid, Departamento de Medicina, Valladolid, Spain
- 1504 ¹⁸³, Hospital Universitario Infanta Leonor, Servicio de Medicina Intensiva, Madrid, Spain
- 1505 ¹⁸⁴, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- 1506 ¹⁸⁵, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
1507 Islas Baleares, Spain
- 1508 ¹⁸⁶, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
1509 Pau, IIB Sant Pau, Barcelona, Spain
- 1510 ¹⁸⁷, Intensive Care Unit, Hospital Universitario N. S. de Candelaria, Santa Cruz de Tenerife,
1511 Spain
- 1512 ¹⁸⁸, Preventive Medicine Department, Instituto de Investigación Sanitaria-Fundación Jiménez
1513 Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1514 ¹⁸⁹, Servicio de Medicina Interna, Sanatorio Franchin, Buenos Aires, Argentina

- 1515 ¹⁹⁰, Hospital Universitario del Tajo, Servicio de Medicina Intensiva, Toledo, Spain
- 1516 ¹⁹¹, Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, Brazil
- 1517 ¹⁹², Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília,
1518 Brazil
- 1519 ¹⁹³, Hospital El Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI), Gerencia
1520 Regional de Salud (SACYL), Ponferrada, Spain
- 1521 ¹⁹⁴, Grupo INVESTEN, Instituto de Salud Carlos III, Madrid, Spain
- 1522 ¹⁹⁵, Unidad de Cuidados Intensivos, Complejo Universitario de A Coruña (CHUAC), Sistema
1523 Galego de Saúde (SERGAS), A Coruña, Spain
- 1524 ¹⁹⁶ Programa de Pós-Graduação em Genética da Faculdade de Medicina de Ribeirão Preto
1525 ¹⁹⁷ Programa de Pós-Graduação em Química da Faculdade de Filosofia, Ciências e Letras de
1526 Ribeirão Preto
1527 ¹⁹⁸, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 1528 ¹⁹⁹, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
- 1529 ²⁰⁰, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos
1530 (HCSC), Madrid, Spain
- 1531 ²⁰¹, Hospital Universitario Severo Ochoa, Servicio de Medicina Interna, Madrid, Spain
- 1532 ²⁰², Universidad de Sevilla, Departamento de Enfermería, Seville, Spain
- 1533 ²⁰³, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 1534 ²⁰⁴, Hospital Universitario La Paz-IDIPAZ, Servicio de Pediatría, Madrid, Spain
- 1535 ²⁰⁵, ERN-ITHACA-European Reference Network
- 1536 ²⁰⁶, Unidad de Genética y Genómica Islas Baleares, Unidad de Diagnóstico Molecular y
1537 Genética Clínica, Hospital Universitario Son Espases, Islas Baleares, Spain
- 1538 ²⁰⁷, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Islas Baleares, Spain
- 1539 ²⁰⁸, Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Brasília, Brazil
- 1540 ²⁰⁹, Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília,
1541 Brazil
- 1542 ²¹⁰, Programa de Pós-Graduação Profissional em Ensino de Biologia, Universidade de Brasília,
1543 Brasília, Brazil
- 1544 ²¹¹, Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, Brazil
- 1545 ²¹², Anatomía Patológica, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital
1546 Clínico San Carlos (HCSC), Madrid, Spain
- 1547 ²¹³, Tecnológico de Monterrey, Monterrey, Mexico
- 1548 ²¹⁴, Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
1549 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 1550 ²¹⁵, Centro de Investigación en Anomalías Congénitas y Enfermedades Raras (CIACER),
1551 Universidad Icesi
- 1552 ²¹⁶, Departamento de Genética, Fundación Valle del Lili
- 1553 ²¹⁷, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and
1554 ENT, Madrid, Spain

- 1555 ²¹⁸, Department of Neumology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
1556 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1557 ²¹⁹, Hospital Nuestra Señora de Sonsoles, Ávila, Spain
- 1558 ²²⁰, Inditex, A Coruña, Spain
- 1559 ²²¹, Osakidetza, Cruces University Hospital, Barakaldo, Bizkaia, Spain
- 1560 ²²², GENYCA, Madrid, Spain
- 1561 ²²³, Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant
1562 Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- 1563 ²²⁴, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
1564 de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
- 1565 ²²⁵, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 1566 ²²⁶, Intensive Care Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
1567 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1568 ²²⁷, Hospital Universitario Príncipe de Asturias, Servicio de Microbiología Clínica, Madrid,
1569 Spain
- 1570 ²²⁸, Universidad de Alcalá de Henares, Departamento de Biomedicina y Biotecnología, Facultad
1571 de Medicina y Ciencias de la Salud, Madrid, Spain
- 1572 ²²⁹, Drug Research Centre, Institut d'Investigació Biomèdica Sant Pau, IIB-Sant Pau, Barcelona,
1573 Spain
- 1574 ²³⁰, Departamento de Genética, Clínica Imbanaco
- 1575 ²³¹, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
1576 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
- 1577 ²³², Universidade de Brasília, Brasília, Brazil
- 1578 ²³³, Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas
1579 de Gran Canaria, Spain
- 1580 ²³⁴, Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran
1581 Canaria, Spain
- 1582 ²³⁵, University Hospital Germans Trias i Pujol, Pediatrics Department, Badalona, Spain
- 1583 ²³⁶, Department of Pathology, Biobank, Instituto de Investigación Sanitaria-Fundación Jiménez
1584 Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1585 ²³⁷, Hospital Universitario Virgen de las Nieves, Servicio de Medicina Interna, Granada, Spain
- 1586 ²³⁸, Fundación Universitaria de Ciencias de la Salud, Grupo de Ciencias Básicas en Salud
1587 (CBS), Bogotá, Colombia
- 1588 ²³⁹, Sociedad de Cirugía de Bogotá, Hospital de San José, Bogotá, Colombia
- 1589 ²⁴⁰, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
1590 Granada, Spain
- 1591 ²⁴¹, Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
- 1592 ²⁴², Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- 1593 ²⁴³, Hospital Universitario Infanta Leonor, Madrid, Spain

- 1594 ²⁴⁴, Complutense University of Madrid, Madrid, Spain
- 1595 ²⁴⁵, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
- 1596 ²⁴⁶ Colégio Militar de Brasília
- 1597 ²⁴⁷, The John Walton Muscular Dystrophy Research Centre, Newcastle University and
- 1598 Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- 1599 ²⁴⁸, Neuromuscular Unit, Neuropediatrics Department, Institut de Recerca Sant Joan de Déu,
- 1600 Hospital Sant Joan de Déu, Spain
- 1601 ²⁴⁹, Fundació Docència i Recerca Mutua Terrassa, Terrassa, Spain
- 1602 ²⁵⁰, Casa de Saúde São Lucas, Natal, Brazil
- 1603 ²⁵¹, Hospital Rio Grande, Rio Grande do Norte, Natal, Brazil
- 1604 ²⁵², Universidade Federal do Rio Grande do Norte, Pós-graduação em Biotecnologia - Rede de
- 1605 Biotecnologia do Nordeste (Renorbio), Natal, Brazil
- 1606 ²⁵³, Intensive Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran
- 1607 Canaria, Spain
- 1608 ²⁵⁴, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
- 1609 ²⁵⁵, Biobank, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain
- 1610 ²⁵⁶, Universidad Rey Juan Carlos, Madrid, Spain
- 1611 ²⁵⁷, Reumatology Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1612 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1613 ²⁵⁸, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiología y Reanimación,
- 1614 Valladolid, Spain
- 1615 ²⁵⁹, Hospital Clinico Universitario de Valladolid, Servicio de Hematología y Hemoterapia,
- 1616 Valladolid, Spain
- 1617 ²⁶⁰, Hospital Universitario Lauro Wanderley, Brazil
- 1618 ²⁶¹, Hospital Universitario Infanta Leonor, Servicio de Medicina Interna, Madrid, Spain
- 1619 ²⁶², University Hospital of Burgos, Burgos, Spain
- 1620 ²⁶³, Universidad de Sevilla, Seville, Spain
- 1621 ²⁶⁴, Fundación Santa Fe de Bogota, Instituto de servicios medicos de Emergencia y trauma,
- 1622 Bogotá, Colombia
- 1623 ²⁶⁵, Universidad de los Andes, Bogotá, Colombia
- 1624 ²⁶⁶, Quironprevención, A Coruña, Spain
- 1625 ²⁶⁷, Junta de Castilla y León, Consejería de Sanidad, Valladolid, Spain
- 1626 ²⁶⁸, Gerencia Atención Primaria de Burgos, Burgos, Spain
- 1627 ²⁶⁹, Immunogenetics-Histocompatibility group, Servicio de Inmunología, Instituto de
- 1628 Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
- 1629 ²⁷⁰, Hospital del Mar, Department of Infectious Diseases, Barcelona, Spain
- 1630 ²⁷¹, IMIM (Hospital del Mar Medical Research Institute, Institut Hospital del Mar
- 1631 d'Investigacions Mediques), Barcelona, Spain
- 1632 ²⁷², Universitat Autònoma de Barcelona, Department of Medicine, Spain

- 1633 ²⁷³, Consejería de Sanidad, Comunidad de Madrid, Madrid, Spain
- 1634 ²⁷⁴, Centro para el Desarrollo de la Investigación Científica, Asunción, Paraguay
- 1635 ²⁷⁵, Internal Medicine Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1636 University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1637 ²⁷⁶, Universidade Federal do Rio Grande do Norte, Programa de Pós Graduação em Nutrição,
- 1638 Natal, Brazil
- 1639 ²⁷⁷, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia
- 1640 de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 1641 ²⁷⁸, Universidade Federal do Rio Grande do Norte, Departamento de Infectologia, Natal, Brazil
- 1642 ²⁷⁹, Hospital de Doenças Infecciosas Giselda Trigueiro, Rio Grande do Norte, Natal, Brazil
- 1643 ²⁸⁰, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de
- 1644 Tenerife, Spain
- 1645
- 1646